

Chemical Compounds with Dual Activity, processes for their preparation and pharmaceutical compositions

The present invention concerns chemical compounds combining affinity and
5 antagonism against the human m₃ muscarinic receptor with activity as selective phosphodiesterase IV (PDE IV) inhibitors, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

Chronic obstructive pulmonary disease is characterised by airway
10 inflammation and impaired expiratory outflow due to chronic bronchitis and/or emphysema. The primary inflammatory cells associated with COPD are macrophages, CD8⁺ T-cells and neutrophils.

Parasympathetic cholinergic reflexes are the most potent tonically active regulators of bronchoconstriction and of submucosal gland exocytosis and secretion in
15 the airways. Post-junctional m₃ receptors mediate cholinergic bronchoconstriction and glandular secretion in the human airways. Prejunctional m₂ autoreceptors modulate the acetylcholine release whereas m₁ receptors located on parasympathetic ganglia inversely facilitate the parasympathetic nerve activity (Barnes P.J., In: "Lung Biology in Health and Disease: Anticholinergic Agents in the Upper and Lower
20 Airways", Vol. 134, Spector S.L. (Ed), (1999), 31-57).

The nasal mucosa of the upper airway is also innervated by parasympathetic nerve fibers, activation of which results in glandular hypersecretion from both goblet cells and submucosal seromucinous glands. Activation of m₁ and m₃ receptors results in secretion from mucous and serous glands. The m₃ receptor subtype, also present on blood vessels, may play an additional role in nasal congestion through
25 promoting vasodilatation.

Thereby, M₃ and M₁ muscarinic receptor antagonists are indicated for the treatment of diseases associated with airway narrowing or/and mucus hypersecretion (Morley, J. Parasympatholytics in Asthma. Pulmonary Pharmacology (1994), 7, 159-
30 168).

Anticholinergic bronchodilators, particularly selective muscarinic M₃ antagonists, are currently the preferred choice for management of COPD as they are more effective and have fewer side effects compared to β₂-adrenoceptor agonists.

Bronchodilators improve symptoms but do not address the underlying chronic
35 inflammation or the changes in airway structure (Hay D.W.P., Current Opinion in Chemical Biology (2000), 4, 412-419).

Amongst phosphodiesterases, PDE IV is the predominant sub-type in inflammatory cells, including mast cells, eosinophils, T lymphocytes, neutrophils and macrophages. It is also the dominant sub-type in structural cells such as sensory nerves and epithelial cells (Torphy T.J., Am. J. Resp. Crit. Care Med. (1998), 157, 351-370).

Standard treatment with corticosteroids as anti-inflammatory agents has demonstrated limited efficacy (Culpitt S.V., Maziak W., Loukidis S., Nightingale J.A., Matthews J.L., Barnes P.J., Am. J. Resp. Crit. Care Med. (1999), 160, 1635-9); Keatings V.M., Jatakanon A., Wordsell Y.M., Barnes P.J., Am. J. Resp. Crit. Care Med. (1997), 155, 542-8). Selective PDE IV inhibitors, however, have proved to be very efficient in attenuating the responses of various inflammatory cells through their ability to elevate cyclic AMP levels. They are known to modulate activity, migration and apoptosis of neutrophils by inhibiting the production and release of chemokines, superoxide free radicals, leukotrienes and proteolytic and toxic granular enzymes (Torphy T.J., Am. J. Resp. Crit. Care Med. (1998), 157, 351-370).


It has now been found that a combination of these two therapeutic activities, bronchodilatation with an M₃ muscarinic antagonist and anti-inflammatory activity with a selective PDE IV inhibitor, in a single compound, provides a new and surprisingly effective approach to the treatment of COPD.

The compounds according to this invention are useful for treating respiratory disorders in connection with Chronic Obstructive Pulmonary Disease (COPD).

Preferred compounds have affinity for the human m₃ muscarinic receptor at concentrations ranging from 100 nM to almost 1 nM and incorporate activity as selective phosphodiesterase IV (PDE IV) inhibitors at concentrations ranging from 2.5 μM to almost 50 nM. These compounds also recognize the m₁, m₂, m₄ and m₅ receptors with variable receptor subtype selectivity.


Preferred compounds have been proven to antagonise carbachol-induced contraction of guinea-pig trachea in vitro.

In one aspect, the invention therefore provide compounds having the formula I, or a pharmaceutically acceptable salt thereof,



wherein

Y is -NH-R² or a group of formula



R¹ is cycloalkyl or non-substituted alkyl ,

R² is cycloalkyl,

R³ is hydrogen, alkyl, halogen, hydroxy, alkoxy or amino,

5 or R²R³ is an alkylene bridging group,

R^a is hydrogen, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, amino, alkylamino, alkylsulfonyloxy, cyano, carboxy, ester or amido,

R^b is hydrogen, alkyl or halogen,

or R^aR^b is carbonyl,

10 R⁴ is hydrogen or alkyl,

R⁵ is cycloalkyl, arylalkyl or heterocycle-alkyl,

or NR⁴R⁵ is a heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom,


15 with the proviso that when Y is -NHR² and R²R³ is an alkylene bridging group or when Y is a group of formula



R¹ is a cycloalkyl.

20 Compounds wherein Y is -NHR² are named compounds Ia.

Compounds wherein Y represents a group of formula



are named compounds Ib.

25 The term "alkyl", as used herein, is defined as including saturated, monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof and containing 1-20 carbon atoms, preferably 1-6 carbon atoms for non-cyclic alkyl and 3-8 carbon atoms for cycloalkyl (in these two preferred cases, unless otherwise specified, "lower alkyl") and includes alkyl moieties substituted by 1 to 5
30 substituents independently selected from the group consisting of halogen, hydroxy, thiol, amino, nitro, cyano, acyl derivative, sulfonyl derivative, sulfinyl derivative, alkylamino, carboxy, ester, ether, amido, azido, cycloalkyl, sulfonic acid, sulfonamide, thio derivative, esteroxy, amidoxy, heterocycle, vinyl, C1-6-alkoxy, C6-10-aryloxy, C6-10-aryl and oxo. "Non-substituted alkyl" represents saturated, monovalent

hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof and containing 1-20 carbon atoms, preferably 1-6 carbon atoms for non-cyclic alkyl and 3-8 carbon atoms for cycloalkyl (in these two preferred cases, unless otherwise specified, "lower alkyl").

5 Preferred alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, and 2,2-dimethylpropyl.

The term "cycloalkyl", as used herein, refers to a monovalent group of 3 to 18 carbons derived from a saturated cyclic or polycyclic hydrocarbon such as adamantyl, which may optionally be substituted with any suitable group, including but not 10 limited to one or more moieties selected from lower alkyl or C6-10-aryl. Non-limiting examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[3.2.1]octyl or adamantyl.

15 The term "alkenyl" as used herein, is defined as including branched, unbranched and cyclic unsaturated hydrocarbon radicals having at least one double bond and being optionally substituted with any suitable group, including but not limited to one or more moieties selected from lower alkyl or other groups as described above for the alkyl groups. Usually "alkenyl" represents branched, unbranched and cyclic unsaturated hydrocarbon radicals having at least one double bond such as 20 ethenyl (= vinyl), 1-methyl-1-ethenyl, 2-methyl-1-propenyl, 1-propenyl, 2-propenyl (= allyl), 1-butenyl, 2-butenyl, 3-butenyl, 4-pentenyl, 1-methyl-4-pentenyl, 3-methyl-1-pentenyl, 1-hexenyl, 2-hexenyl, and the like.

25 The term "alkynyl" as used herein, is defined as including a branched, unbranched and cyclic hydrocarbon radical containing at least one carbon-carbon triple bond and being optionally substituted by any suitable group, including but not limited to one or more moieties selected from lower alkyl or other groups as described above for the alkyl groups. Usually "alkynyl" represents branched, unbranched and cyclic hydrocarbon radical containing at least one carbon-carbon triple bond such as ethynyl, 2-propynyl (= propargyl), and the like.

30 The term "alkylene" as used herein, is defined as including branched, unbranched and cyclic divalent hydrocarbon radicals containing 1-12 carbon atoms, preferably 1-4 carbon atoms, being optionally substituted with any suitable group, including but not limited to one or more moieties selected from lower alkyl or other groups as described above for the alkyl groups.

35 When present as bridging groups, alkyl represents straight or branched chains, C1-12-, preferably C1-4-alkylene.

Groups where branched derivatives are conventionally qualified by prefixes such as "n", "sec", "iso" and the like (e.g. "n-propyl", "sec-butyl") are in the n-form unless otherwise stated.

The term "halogen", as used herein, includes an atom of Cl, Br, F, I.

The term "hydroxy", as used herein, represents a group of the formula -OH.

The term "amino", as used herein, represents a group of the formula -NH₂.

The term "thiol", as used herein, represents a group of the formula -SH.

5 The term "cyano", as used herein, represents a group of the formula -CN.

The term "nitro", as used herein, represents a group of the formula -NO₂.

The term "alkoxy", as used herein, is defined as including -O-R⁶ groups wherein R⁶ represents an alkyl or a cycloalkyl group. Non-limiting examples are methoxy and ethoxy.

10 The term "arylalkyl", as used herein, represents a group of the formula -R⁷-aryl in which R⁷ is C1-12- straight, branched or cyclic alkylene. Non-limiting examples are benzyl, halobenzyl, cyanobenzyl, methoxybenzyl, nitrobenzyl, 2-phenylethyl, diphenylmethyl, (4-methoxyphenyl)diphenylmethyl and anthracenylmethyl.

15 The term "aryl" as used herein, is defined as including an organic radical derived from an aromatic hydrocarbon consisting of 1-3 rings and containing 6-30 carbon atoms by removal of one hydrogen, such as phenyl and naphthyl each optionally substituted by 1 to 5 substituents independently selected from halogen, hydroxy, thiol, amino, nitro, cyano, C1-6-alkoxy, C1-6-alkylthio, C1-6-alkyl, C1-6-haloalkyl. Aryl radicals are preferably monocyclic containing 6-10 carbon atoms.

20 Preferred aryl groups are phenyl and naphthyl each optionally substituted by 1 to 5 substituents independently selected from halogen, nitro, amino, azido, C1-6-alkoxy, C1-6-alkylthio, C1-6-alkyl and C1-6-haloalkyl.

25 The term "alkylthio", as used herein, is defined as including -S-R^{6a} groups wherein R^{6a} represents an alkyl or a cycloalkyl group. Non-limiting examples are methylthio, ethylthio, propylthio and butylthio.

30 The term "heterocycle", as used herein is defined as including an aromatic or non aromatic cyclic alkyl, alkenyl, or alkynyl moiety as defined above, having at least one O, S and/or N atom interrupting the carbocyclic ring structure and optionally, one of the carbon of the carbocyclic ring structure may be replaced by a carbonyl. Non-limiting examples of aromatic heterocycles are pyridyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, quinazolinyl, quinolizinyl, naphthyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolyl, isobenzofuranyl, benzothienyl, pyrazolyl, indolyl, indolizinyl, purinyl, isoindolyl, carbazolyl, thiazolyl, 1,2,4-thiadiazolyl, thieno(2,3-b)furan, fuopyranyl, benzofuranyl, benzoepinyl, isooxazolyl, oxazolyl, thianthrenyl, benzothiazolyl, or benzoxazolyl, cinnolinyl, phthalazinyl, quinoxalinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenothiazinyl, furazanyl, isochromanyl, indolinyl,

xanthenyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl optionally substituted by alkyl or as described above for the alkyl groups. Non-limiting examples of non aromatic heterocycles are tetrahydrofuranyl, tetrahydropyrananyl, piperidinyl, piperidyl, 5 piperazinyl, imidazolidinyl, morpholino, morpholinyl, 1-oxaspiro(4.5)dec-2-yl, pyrrolidinyl, 2-oxo-pyrrolidinyl, 8-thia bicyclo[3.2.1]cyclooctanyl, 1,4-dithiepanyl, tetrahydro-2H-thiopyrananyl, azepanyl, azocanyl, or the same which can optionally be substituted with any suitable group, including but not limited to one or more moieties selected from lower alkyl, alkylidene or other groups as described above for the alkyl 10 groups. The term "heterocycle" also includes bicyclic, tricyclic and tetracyclic, spiro groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from an aryl ring, a cycloalkyl ring, a cycloalkenyl ring or another monocyclic heterocyclic ring or where a monocyclic heterocyclic group is bridged by an alkylene group, such as quinuclidinyl, 7-azabicyclo(2.2.1)heptanyl, 7-15 oxabicyclo(2.2.1)heptanyl, 8-azabicyclo(3.2.1)octanyl.

The term "heterocycle-alkyl", as used herein, represents a group of the formula -R⁷-heterocycle in which R⁷ is C1-12- straight, branched or cyclic alkylene. Non-limiting examples are thiophenemethyl, thiophenethyl, pyridylmethyl and pyridylethyl.

The term "amido", as used herein, is defined as including a group of formula -CONR⁸R⁹ wherein R⁸ and R⁹ are the same or different and each is independently a hydrogen, alkyl or aryl group as defined above.

The term "alkylamino", as used herein, is defined as including a group of formula -NR¹⁰R¹¹ wherein R¹⁰ and R¹¹ are the same or different and each is independently hydrogen or an alkyl group as defined above, with the proviso that at 25 least one of R¹⁰ and R¹¹ is not hydrogen.

The term "pharmaceutically acceptable salt" according to the invention includes therapeutically active, non-toxic base and acid salt forms which the compounds of formula I are able to form.

The acid addition salt form of a compound of formula I that occurs in its free form as a base can be obtained by treating the free base with an appropriate acid such as an inorganic acid, for example, a hydrohalic such as hydrochloric or hydrobromic, sulfuric, nitric, phosphoric and the like; or an organic acid, such as, for example, acetic, hydroxyacetic, propanoic, lactic, pyruvic, malonic, succinic, maleic, fumaric, 30 malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like.

The compounds of formula I containing acidic protons may be converted into their therapeutically active, non-toxic base addition salt forms, e.g. metal or amine

salts, by treatment with appropriate organic and inorganic bases. Appropriate base salt forms include, for example, ammonium salts, alkali and earth alkaline metal salts, e.g. lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

Conversely said salt forms can be converted into the free forms by treatment with an appropriate base or acid.

Compounds of the formula I and their salts can be in the form of a solvate, which is included within the scope of the present invention. Such solvates include for example hydrates, alcoholates and the like.

Some of the compounds of formula I and some of their intermediates have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondance with the rules described in Pure Appl. Chem., 45 (1976) 11-30.

The invention also relates to all stereoisomeric forms such as enantiomeric and diastereomeric forms of the compounds of formula I or mixtures thereof (including all possible mixtures of stereoisomers). Reference to a compound or compounds is intended to encompass that compound in each of its possible isomeric forms and mixtures thereof unless the particular isomeric form is referred to specifically.

Some of the compounds of formula I may also exist in tautomeric forms. Such forms although not explicitly indicated in the above formula, are intended to be included within the scope of the present invention.


The invention also includes within its scope pro-drug forms of the compounds of formula I and its various sub-scopes and sub-groups.

The term "prodrug" as used herein includes compound forms which are rapidly transformed in vivo to the parent compound according to the invention, for example, by hydrolysis in blood. Prodrugs are compounds bearing groups which are removed by biotransformation prior to exhibiting their pharmacological action. Such groups include moieties which are readily cleaved in vivo from the compound bearing it, which compound after cleavage remains or becomes pharmacologically active.

Metabolically cleavable groups form a class of groups well known to practitioners of the art. They include, but are not limited to such groups as alkanoyl (i.e. acetyl, propionyl, butyryl, and the like), unsubstituted and substituted carbocyclic aroyl (such as benzoyl, substituted benzoyl and 1- and 2-naphthoyl), alkoxy carbonyl (such as ethoxycarbonyl), trialkylsilyl (such as trimethyl- and triethylsilyl), monoesters formed with dicarboxylic acids (such as succinyl), phosphate, sulfate, sulfonate,

sulfonyl, sulfinyl and the like. The compounds bearing the metabolically cleavable groups have the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or rate of absorption conferred upon the parent compound by virtue of the presence of the metabolically cleavable group. T. Higuchi and V. Stella,
 5 "Pro-drugs as Novel Delivery System", Vol. 14 of the A.C.S. Symposium Series;
 "Bioreversible Carriers in Drug Design", ed. Edward B. Roche, American
 Pharmaceutical Association and Pergamon Press, 1987.

According to a first embodiment of the invention compounds are compounds of
 10 formula Ia



or a pharmaceutically acceptable salt thereof wherein R¹, R², R³, R⁴ and R⁵ are as defined above.

Usually, R¹ is C3-7-cycloalkyl or non-substituted alkyl.

15 Usually, R² is C3-7-cycloalkyl, R³ being as defined above, or R²R³ is a C2-4 alkylene bridging group.

Usually, R³ is hydrogen, C1-4-alkyl, halogen, hydroxy, alkoxy or amino, R² being as defined above, or R²R³ is a C2-4 alkylene bridging group.

20 Usually, R⁴ is hydrogen or C1-4-alkyl, R⁵ being as defined above, or NR⁴R⁵ is a heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom.

Usually, R⁵ is C3-7-cycloalkyl, arylalkyl or heterocycle-alkyl, R⁴ being as defined above, or NR⁴R⁵ is a heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom.

Generally R¹ is a non-substituted alkyl, a non-substituted cycloalkyl, a cycloalkyl substituted by a lower alkyl, or an alkyl substituted by a cycloalkyl.

30 Preferably, R¹ is C3-4-alkyl or C3-5-cycloalkyl, more preferably R¹ is selected from the group of cyclopropyl, isopropyl, cyclobutyl, cyclopentyl, 2-methyl-cyclopropyl and cyclopropylmethyl.

Generally R² is a non-substituted cycloalkyl, or a cycloalkyl substituted by a lower alkyl or an aryl.

Preferably, R² is a non-substituted C3-4-cycloalkyl. More preferably R² is selected from cyclopropyl or cyclobutyl.

5

Generally R³ is hydrogen, halogen, amino, non-substituted alkoxy or a non-substituted alkyl.

Preferably, R³ is hydrogen, methyl, ethyl, a Cl atom, a F atom, a Br atom, amino or methoxy.

10

In other preferred embodiments R²R³ is an alkylene bridging group selected from ethylene, propylene and butylene.

Generally R⁴ is hydrogen or a non-substituted alkyl.

15

Preferably, R⁴ is hydrogen or C1-4-alkyl. More preferably R⁴ is hydrogen or methyl.

20

Preferably, R⁵ is 2-(2-thienyl)ethyl, 2-furylmethyl, 2-thienylmethyl, 4-pyridinylmethyl, benzyl, 2-(methylsulfanyl)benzyl, 2,6-difluorobenzyl, 2-fluorobenzyl, 2-nitrobenzyl, 3,5-bis(trifluoromethyl)benzyl, 3,5-difluorobenzyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, or 2,2-diphenylethyl.

25

30

35

In other preferred embodiments, NR⁴R⁵ is 1,3-thiazolidin-3-yl, 1-azepanyl, 1-azocanyl, 3,5-dimethyl-1-piperidinyl, 4-(2-methoxyphenyl)-1-piperidinyl, 4-(hydroxy(diphenyl)methyl)-1-piperidinyl, 4-(trifluoromethyl)-1-piperidinyl, 4,4-difluoro-1-piperidinyl, 4,4-dimethyl-1-piperidinyl, 4-carbamoyl-1-piperidinyl, 4-benzyl-1-piperidinyl, 4-carboxy-1-piperidinyl, 4-cyano-4-phenyl-1-piperidinyl, 4-ethoxycarbonyl-1-piperidinyl, 4-ethyl-1-piperidinyl, 4-ethyl-4-methyl-1-piperidinyl, 4-hydroxy-1-piperidinyl, 4-hydroxy-4-phenyl-1-piperidinyl, 4-hydroxymethyl-1-piperidinyl, 4-methyl-1-piperidinyl, 4-methylene-1-piperidinyl, 4-oxo-1-piperidinyl, 3,6-dihydro-1(2H)-pyridinyl, 3-azabicyclo[3.2.1]oct-3-yl, 4-thiomorpholinyl, 2-one-1-azepanyl, 3,4-dihydro-2(1H)-isoquinolinyl, 1,4-dioxa-8-azaspiro[4.5]dec-8-yl, 1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl, octahydro-2(1H)-isoquinolinyl or 8-azaspiro[4.5]dec-8-yl.

Combinations of one or more of these preferred compound groups are especially preferred.

More preferred compounds Ia are:


6-(1-azepanyl)-2-cyclobutyl-N-cyclopropyl-5-methyl-4-pyrimidinamine; 6-(1-azepanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; 6-(1-azepanyl)-5-chloro-N,2-dicyclopropyl-4-pyrimidinamine; 6-(1-azepanyl)-N,2-dicyclopropyl-5-fluoro-4-pyrimidinamine; 6-azepan-1-yl-5-bromo-N,2-dicyclopropyl-4-pyrimidinamine; 6-(1-azepanyl)-N,2-dicyclopropyl-4-pyrimidinamine; 6-(1-azepanyl)-N⁴,2-dicyclopropyl-4,5-pyrimidinediamine; 6-(1-azepanyl)-N-cyclopropyl-2-isopropyl-5-methyl-4-pyrimidinamine; 6-(1-azepanyl)-N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-4-pyrimidinamine; 6-(1-azocanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-[4-(trifluoromethyl)piperidin-1-yl]-4-pyrimidinamine; N,2-dicyclopropyl-6-(4,4-difluoro-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-6-(4,4-dimethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-6-(4-ethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-ethyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-methylene-1-piperidinyl)-4-pyrimidinamine; N,2-dicyclopropyl-6-(3,6-dihydro-1(2H)-pyridinyl)-5-methyl-4-pyrimidinamine; 6-(3-azabicyclo[3.2.1]oct-3-yl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-ethyl-6-(4-thiomorpholinyl)-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-thiomorpholinyl)-4-pyrimidinamine; N⁴,2-dicyclopropyl-N⁶-(2,6-difluorobenzyl)-5-methyl-4,6-pyrimidinediamine; N⁴-cyclohexyl-N⁶-cyclopropyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediamine; N⁴,2-dicyclopropyl-5-methyl-N⁶-(4-methylcyclohexyl)-4,6-pyrimidinediamine; 6-(1-azepanyl)-2-cyclopentyl-N-cyclopropyl-5-methyl-4-pyrimidinamine; 4-azepan-1-yl-2-cyclopropyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine; 4-azepan-1-yl-2-cyclopropyl-6,7,8,9-tetrahydro-pyrimido[4,5-b]azepine; N,2-dicyclopropyl-5-methyl-6-(1-piperidinyl)-4-pyrimidinamine; 6-(3-azabicyclo[3.2.2]non-3-yl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(2-methyl-1-piperidinyl)-4-pyrimidinamine and N,2-dicyclopropyl-5-methyl-6-(1-pyrrolidinyl)-4-pyrimidinamine, stereoisomeric forms or mixtures thereof, or pharmaceutically acceptable salts thereof.

Most preferred compounds Ia are:

6-(1-azepanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-6-(4,4-dimethyl-1-piperidinyl)-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine; 6-(3-azabicyclo[3.2.1]oct-3-yl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine; N,2-dicyclopropyl-5-methyl-6-(4-thiomorpholinyl)-4-pyrimidinamine; 4-azepan-1-yl-2-


cyclopropyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine and 4-azepan-1-yl-2-cyclopropyl-6,7,8,9-tetrahydro-pyrimido[4,5-b]azepine, or pharmaceutically acceptable salts thereof.

5 According to another embodiment of the invention, compounds are compounds Ib, or a pharmaceutically acceptable salt thereof,



wherein

Y is a group of formula



10

and R¹, R³, R^a, R^b, R⁴ and R⁵ are as defined above.

Usually, R¹ is C3-7-cycloalkyl.

Usually, R³ is hydrogen, C1-4-alkyl, halogen, hydroxy, alkoxy or amino.

15 Usually, R^a is hydrogen, C1-4-alkyl, C2-6-alkenyl, C2-6-alkynyl, halogen, hydroxy, alkoxy, amino, alkylamino, alkylsulfonyloxy, cyano, carboxy, ester or amido, R^b being as defined above, or R^aR^b is carbonyl.

Usually, R^b is hydrogen, C1-4-alkyl or halogen, R^a being as defined above, or R^aR^b is carbonyl.

20 Usually, NR⁴R⁵ is a heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom.

25 Generally, R¹ is a non-substituted C3-7-cycloalkyl, or a C3-7-cycloalkyl substituted by a lower alkyl.

Preferably, R¹ is C3-4-cycloalkyl. More preferably, R¹ is cyclopropyl.

Generally R³ is hydrogen, halogen, amino, non-substituted alkoxy or a non-substituted C1-4-alkyl.

30 Preferably, R³ is hydrogen or C1-4-alkyl. More preferably, R³ is hydrogen or methyl.

Generally, R^a is hydrogen, C1-4-alkyl, halogen, hydroxy, alkoxy, alkylsulfonyloxy or cyano.

Preferably, R^a is hydrogen, methyl, hydroxy, methoxy, methylsulfonyloxy, a Br atom, a F atom or cyano. More preferably, R^a is hydrogen, methyl, hydroxy or a F atom.

5 Generally, R^b is hydrogen or C1-4-alkyl.

Preferably, R^b is hydrogen or methyl. More preferably, R^b is hydrogen.

In other preferred embodiments R^aR^b is carbonyl.

10 Preferably, NR⁴R⁵ is a 5- to 9-membered heterocycle, which may be substituted, containing only one heteroatom which is a nitrogen atom or containing two heteroatoms wherein one is a nitrogen atom and the other is a non-oxidized sulfur atom. More preferably, NR⁴R⁵ is 1-azepanyl.

15 Combinations of one or more of these preferred compound groups are especially preferred.

More preferred compounds Ib are:

20 1-(6-azetidin-1-yl-2-cyclopropyl-5-methylpyrimidin-4-yl)azepane; 1-[2-cyclopropyl-5-methyl-6-(3-methylazetidin-1-yl)pyrimidin-4-yl]azepane; 1-(6-azepan-1-yl-2-cyclopropyl-5-methylpyrimidin-4-yl)azetidin-3-ol; 1-[2-cyclopropyl-6-(3-methylazetidin-1-yl)pyrimidin-4-yl]azepane; 1-(6-azetidin-1-yl-2-cyclopropylpyrimidin-4-yl)azepane and 1-[2-cyclopropyl-6-(3-fluoroazetidin-1-yl)-5-methylpyrimidin-4-yl]azepane, or pharmaceutically acceptable salts thereof.

25 Most preferred compounds Ib are:


1-(6-azetidin-1-yl-2-cyclopropyl-5-methylpyrimidin-4-yl)azepane and 1-[2-cyclopropyl-5-methyl-6-(3-methylazetidin-1-yl)pyrimidin-4-yl]azepane, or pharmaceutically acceptable salts thereof.

30 The present invention concerns also processes for preparing the compounds of formula I.

The following process description sets forth certain synthesis processes in an illustrative manner. Other alternative and/or analogous methods will be readily apparent to those skilled in this art.

35 **A.** According to one embodiment, compounds having the general formula I wherein R³ = H, alkyl, halogen, alkoxy or hydroxy may be prepared by reaction of a


compound of formula II wherein R^3 = H, alkyl, halogen, alkoxy or hydroxy with an amine of formula III according to the equation:




5 This reaction may be carried out without solvent in the case of high-boiling point amines of formula III or in a high-boiling point alcohol (e.g.: 1-methoxy-2-propanol) as solvent in the case of solid or low boiling point amines of formula III, between 80 and 130 °C.

10 Compounds of formula III are commercially available or may be prepared under any conventional methods known to the person skilled in the art.

Compounds of formula II



15 wherein R^3 = H, alkyl, halogen, alkoxy or hydroxy may be prepared by reaction of a compound of formula IV wherein R^3 = H, alkyl, halogen, alkoxy or hydroxy either with a primary amine of formula Va (leading to compounds IIa), or a with an azetidine of formula Vb (leading to compounds IIb) according to the equations:




These reactions may be carried out without solvent or in dichloromethane as a solvent, between 30 and 60 °C, in the presence of a base such as potassium carbonate in the case of an azetidine hydrochloride.

Compounds of formula Va are commercially available and compounds of formula Vb are either commercially available or may be prepared under any conventional method known to the person skilled in the art.

5 As an example, 3-fluoroazetidine hydrochloride may be prepared by catalytic hydrogenation of 1-benzhydryl-3-fluoroazetidine. This reaction can be performed by any person skilled in the art.


1-benzhydryl-3-fluoroazetidine may be prepared by fluorination of 1-benzhydryl-3-methanesulfonyloxy-azetidine. This reaction may be carried out in boiling acetonitrile in the presence of tetrabutylammonium fluoride as a fluorinating agent as described in: Berkin A., Szarek W.A., Kisilevsky R., Carbohydr. Res. (2000), 326, 250-263.

Compounds of formula IV wherein $R^3 = H$, alkyl, halogen, alkoxy or hydroxy may be prepared by reaction of a compound of formula VI wherein $R^3 = H$, alkyl, halogen, alkoxy or hydroxy with phosphorus oxychloride according to the equation:



This reaction may be carried out in boiling phosphorus oxychloride in the presence of one equivalent of N,N-diethylaniline as described in: Evans R.F., Savage G.P., Gough D.A., Aust. J. Chem. (1990), 43, 733-740 or in: Biagi G., Giorgi I., Livi O., Scartoni V., Lucacchini A., Farmaco (1997), 52, 61-66.

Compounds of formula VI wherein R³ = H, alkyl, halogen, alkoxy or hydroxy may be prepared by reaction of a compound of formula VII with a dialkylmalonate of formula VIII wherein R³ = H, alkyl, halogen, alkoxy or hydroxy and R⁸ = C1-4-alkyl according to the equation:



This reaction may be carried out in an alcoholic solvent, for example methanol or ethanol, in the presence of 2 equivalents of metallic sodium as a base between 60 and 80 °C as described in: Gershon H., Braun R., Scala A., Rodin R., J. Med. Chem. (1964), 7, 808.

Compounds of formula VIII are commercially available or may be prepared under any conventional method known to the person skilled in the art.


5 Compounds of formula VII are commercially available or may be prepared from the corresponding nitrile IX according to the equation:



This reaction may be carried out as described in: Moss R.A., Liu W., Krogh-Jespersen K., Tetrahedron Lett. (1993), 34, 6025-6028.

B. According to another embodiment, compounds having the general formula I wherein R³ = NH₂ may be prepared by reduction of the corresponding compound of formula I-A according to the equation:

15




This reaction may be carried out by any conventional method known to the person skilled in the art, for example aqueous sodium dithionite in dioxane in the presence of ammonia as described in: Chorvat R.J. et al., J. Med. Chem. (1999), 42,

20 833-848.


Compounds of formula I-A wherein R³ = NO₂ may be prepared from a compound VI wherein R³ = NO₂ following the procedure described in A, using compound of formula

25



as an intermediate.


Compounds of formula VI wherein $R^3 = NO_2$ may be prepared by reaction of the corresponding compound of formula VI wherein $R^3 = H$ with nitric acid according to the equation:



5

This reaction may be carried out using fuming nitric acid in glacial acetic acid between 30 and 40 °C as described in: Beck J.P. et al., Bioorg. Med. Chem. Lett. (1999), 9, 967 or in: Bagli J. et al., J. Med. Chem. (1988), 31, 814.


10 C. According to another embodiment, compounds having the general formula I wherein $R^3 = Br$ may be prepared by bromination using N-bromosuccinimide (NBS) of a compound of formula I wherein $R^3 = H$ according to the equation:



15


This reaction may be carried out in chloroform as described in: Chen C., Dagnino R., De Souza E.B., Grigoriadis, D.E., Huang C.Q., J. Med. Chem. (1996) 39, 4358-4360.

D. According to another embodiment, compounds having the general formula Ia wherein R^2R^3 is an alkylene bridging group of formula $-(CH_2)_n-CH_2-$, with $n = 1-6$ may be prepared by reaction of a compound of formula X wherein $n = 1-6$ with an amine of formula III according to the equation:




This reaction may be carried out without solvent in the case of high-boiling point amines of formula III or in a high-boiling point alcohol (e.g.: 1-methoxy-2-propanol) as solvent in the case of solid or low boiling point amines of formula III, between 80 and 130 °C.

D.1 Compounds of formula X wherein n = 2-6 may be prepared by heating a compound of formula IV wherein R³ represents -CH₂-(CH₂)_n-NH₂ with n = 2-6 according to the equation:



5 This reaction may be carried out in a high-boiling point alcohol (e.g.: 1-methoxy-2-propanol) as solvent, between 120 and 140 °C.


Compounds of formula IV wherein R³ represents -CH₂-(CH₂)_n-NH₂, with n = 2-6, may be prepared by reaction of a compound of formula VI wherein R³ represents CH₂-(CH₂)_n-NHBoc, with n = 2-6, with phosphorus oxychloride according to the equation:



This reaction may be carried out in boiling phosphorus oxychloride in the presence of 1 equivalent of N,N-diethylaniline as described in Evans R.F., Savage G.P., Gough D.A., Aust. J. Chem. (1990), 43, 733-740 or in: Biagi G., Giorgi I., Livi O., Lucacchini A., Farmaco (1997), 52, 61-66.

Compounds of formula VI wherein R³ represents -CH₂-(CH₂)_n-NHBOC, with n = 2-6, may be prepared by reaction of a compound of formula VII with a dialkylmalonate of formula VIII wherein R³ represents -CH₂-(CH₂)_n-NHBOC, with n = 2-6, according to the procedure described in A.

25 Compounds of formula VIII wherein R³ represents -CH₂-(CH₂)_n-NHBOC, with n = 2-6, may be prepared by reaction the corresponding compound of formula VIII wherein R³ = H and R⁸ = C1-4-alkyl with a compound of formula XI wherein L is a leaving group according to the equation:




This reaction may be carried out starting from protected alkyl amines bearing a leaving group L (e.g.: halogen, mesylate) in an alcoholic solvent, for example methanol or ethanol, in the presence of 2 equivalents of metallic sodium as a base between 60 and 80 °C.

5

Compounds of formula VIII are commercially available.

Compounds of formula XI may be prepared by any conventional methods known to the person skilled in the art.

- 10 D.2 Compounds of formula X wherein n = 1 may be prepared by reaction of a compound of formula XII with phosphorus oxychloride according to the equation:




15

This reaction may be carried out in boiling phosphorus oxychloride.

Compounds of formula XII may be prepared by reaction of a compound of formula VII with 2-ethoxy-4,5-dihydro-3H-pyrrole-3-carboxylic acid ethyl ester (XIII) according to the equation:

20



25


This reaction may be carried out in an alcoholic solvent, for example methanol or ethanol, in the presence of 1 equivalent of metallic sodium as a base between 60 and 80 °C as described in: Gershon H., Braun R., Scala A., Rodin R., J. Med. Chem. (1964), 7, 808 and in: Granik V.G., Glushkov R.G., Pharm. Chem. J. (Engl. Transl.) (1967), 5, 247-249.

2-Ethoxy-4,5-dihydro-3*H*-pyrrole-3-carboxylic acid ethyl ester of formula (XIII) may be prepared as described in: Granik V.G., Glushkov R.G., Pharm. Chem. J. (Engl. Transl.) (1967), 5, 247-249 and in: Lindstrom K.J., Crooks S.L., Synth. Commun. (1990), 2335-2337.

5

E. According to another embodiment, compounds having the general formula Ib wherein R^a = Br may be prepared by bromination using sodium bromide of a compound of formula Ib wherein R^a = OSO₂CH₃ according to the equation:

10




This reaction may be carried out in N,N-dimethylformamide between 80 and 120 °C as described in: Okada T., Ezumi K., Yamakawa M., Sato H., Tsuji T., Chem Pharm. Bull. (1993), 41, 126-131.

15

Compounds having the general formula Ib wherein R^a = OSO₂CH₃ may be prepared by mesylation using methanesulfonyl chloride of a compound of formula Ib wherein R^a = OH. This reaction may be carried out by any person skilled in the art.

20

F. According to another embodiment, compounds having the general formula Ib wherein R^a = CN may be prepared by cyanation using sodium cyanide of a compound of formula Ib wherein R^a = OSO₂CH₃ according to the equation:




25

This reaction may be carried out in N,N-dimethylformamide between 80 and 120 °C as described in: Frigola J., Pares J., Corbera J., Vano D., Merce R., J. Med. Chem. (1993), 36, 801-810.

G. According to another embodiment, compounds having the general formula Ib wherein R^aR^b = carbonyl may be prepared by oxidation using sulfur

trioxide/pyridine complex of a compound of formula Ib wherein R^a = OH according to the equation:




This reaction may be carried out in dimethylsulfoxide at room temperature as described in: Katritzky A.R., Cundy D.J., Chen J., *J. Heterocyclic Chem.* (1994), 31, 271-276.

When compounds of formula I present one or several stereogenic centres, and that non-stereoselective methods of synthesis are used, resolution of the mixture of stereoisomers can best be effected in one or several steps, involving generally sequential separation of mixtures of diastereomers into their constituting racemates, using preferably chromatographic separations on achiral or chiral phase in reversed or preferably in direct mode, followed by at least one ultimate step of resolution of each racemate into its enantiomers, using most preferably chromatographic separation on chiral phase in reversed or preferably in direct mode. Alternatively, when partly stereoselective methods of synthesis are used, the ultimate step may be a separation of diastereomers using preferably chromatographic separations on achiral or chiral phase in reversed or preferably in direct mode.


20

In another embodiment, the present invention concerns also the synthesis intermediates of formula II



wherein Y, R¹ and R² are as defined above, R³ is hydrogen, alkyl, halogen, alkoxy or hydroxy, R^a is hydrogen, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, amino, alkylamino, alkylsulfonyloxy, cyano, carboxy, ester or amido, and R^b is hydrogen, alkyl or halogen or R^aR^b is carbonyl.

In synthesis intermediates of formula II, when Y represents a group of formula




then R¹ is preferably cycloalkyl, more preferably cyclopropyl and R³ is preferably hydrogen or alkyl, more preferably hydrogen or methyl.

In a preferred embodiment, the present invention also concerns the synthesis
5 intermediates selected from the group consisting of 6-chloro-N,2-dicyclopropyl-5-
fluoro-4-pyrimidinamine; 6-chloro-N,2-dicyclopropyl-4-pyrimidinamine; 6-chloro-N,2-
dicyclopropyl-5-methyl-4-pyrimidinamine; 5,6-dichloro-N,2-dicyclopropyl-4-
pyrimidinamine; 6-chloro-N,2-dicyclopropyl-5-methoxy-4-pyrimidinamine; 6-chloro-
N,2-dicyclopropyl-5-ethyl-4-pyrimidinamine; N-[6-chloro-2-(2-trans-
10 methylcyclopropyl)-4-pyrimidinyl]-N-cyclopropylamine and its enantiomers; 6-chloro-
N-cyclopropyl-5-methyl-2-(2-trans-methylcyclopropyl)-4-pyrimidinamine; 6-chloro-N-
cyclopropyl-5-methyl-2-(2-cis-methylcyclopropyl)-4-pyrimidinamine; N-[6-chloro-2-
(cyclopropylmethyl)-5-methyl-4-pyrimidinyl]-N-cyclopropylamine; 6-chloro-2-
cyclobutyl-N-cyclopropyl-5-methyl-4-pyrimidinamine; 6-chloro-N-cyclobutyl-2-
15 cyclopropyl-5-methyl-4-pyrimidinamine; 6-chloro-N-cyclopropyl-2-isopropyl-5-methyl-
4-pyrimidinamine; 6-chloro-2-cyclopentyl-N-cyclopropyl-5-methyl-4-pyrimidinamine;
6-chloro-2-cyclopropyl-5-methyl-N-(2-methylcyclopropyl)-4-pyrimidinamine; 6-chloro-2-
20 cyclopropyl-5-methyl-N-(1-methylcyclopropyl)-4-pyrimidinamine; 6-chloro-2-
cyclopropyl-5-methyl-N-(2-phenylcyclopropyl)-4-pyrimidinamine; 4-(1-azetidinyl)-6-
chloro-2-cyclopropyl-5-methylpyrimidine; 4-(1-azetidinyl)-6-chloro-2-
cyclopropylpyrimidine; 4-chloro-2-cyclopropyl-5-methyl-6-(3-methyl-1-
25 azetidinyl)pyrimidine; 4-chloro-2-cyclopropyl-6-(3-methyl-1-azetidinyl)pyrimidine; 4-
chloro-2-cyclopropyl-6-(3,3-dimethyl-1-azetidinyl)-5-methylpyrimidine; 1-(6-chloro-2-
cyclopropyl-5-methyl-4-pyrimidinyl)-3-azetidinol; 4-chloro-2-cyclopropyl-6-(3-fluoro-1-
azetidinyl)-5-methylpyrimidine; 4-chloro-2-cyclopropyl-6-(3-fluoro-1-
30 azetidinyl)pyrimidine and 4-chloro-2-cyclopropyl-6-(3-methoxy-1-azetidinyl)-5-
methylpyrimidine.

In another embodiment, the present invention concerns the following synthesis
30 intermediate of formula II-A: 6-chloro-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine.

In another embodiment, the present invention concerns the following synthesis
intermediate of formula VII: 2-methylcyclopropanecarboximidamide.

35 In another embodiment, the present invention concerns the synthesis
intermediates of formula VI



wherein R^1 is alkyl or cycloalkyl and R^3 is alkoxy. Usually, R^1 is alkyl or C3-5-cycloalkyl.

5 In a preferred embodiment, the present invention also concerns the synthesis intermediates selected from the group consisting of: 2-cyclopropyl-5-fluoro-4,6-pyrimidinediol; 5-chloro-2-cyclopropyl-4,6-pyrimidinediol; 2-cyclopropyl-5-methoxy-4,6-pyrimidinediol; 2-cyclopropyl-5-ethyl-4,6-pyrimidinediol; 2-(2-methylcyclopropyl)-4,6-pyrimidinediol; 5-methyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediol; 2-(cyclopropylmethyl)-5-methyl-4,6-pyrimidinediol; 2-cyclobutyl-5-methyl-4,6-pyrimidinediol; 2-isopropyl-5-methyl-4,6-pyrimidinediol; 2-cyclopentyl-5-methyl-4,6-pyrimidinediol; [3-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-propyl]-carbamic acid tert-butyl ester and [4-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-butyl]-carbamic acid tert-butyl ester.


10

15 In another embodiment, the present invention concerns the following synthesis intermediates of formula IV: 4,6-dichloro-2-cyclopropyl-5-fluoropyrimidine; 4,5,6-trichloro-2-cyclopropylpyrimidine; 4,6-dichloro-2-cyclopropyl-5-pyrimidinyl methyl ether; 4,6-dichloro-2-cyclopropyl-5-ethylpyrimidine; 4,6-dichloro-2-(2-methylcyclopropyl)pyrimidine; 4,6-dichloro-5-methyl-2-(2-methylcyclopropyl)pyrimidine; 4,6-dichloro-2-(cyclopropylmethyl)-5-methylpyrimidine; 4,6-dichloro-2-cyclobutyl-5-methylpyrimidine; 4,6-dichloro-2-isopropyl-5-methylpyrimidine and 4,6-dichloro-2-cyclopentyl-5-methylpyrimidine.

20

25 In another embodiment, the present invention concerns the following synthesis intermediate of formula I-A: 6-(1-azepanyl)-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine.

30 In another embodiment, the present invention concerns the synthesis intermediates of formula X




wherein n is 1-6 and R^1 is cycloalkyl.

Preferably, the synthesis intermediates of formula X are selected from the group consisting of: 4-chloro-2-cyclopropyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine; 4-chloro-2-cyclopropyl-5,6,7,8-tetrahydro-5H-pyrido[2,3-*d*]pyrimidine and 4-chloro-2-cyclopropyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-*b*]azepine.

5

In another embodiment, the present invention concerns the synthesis intermediates of formula XII



wherein R¹ is cycloalkyl.

10

Preferably, the synthesis intermediate of formula XII is 2-cyclopropyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidin-4-ol.

15

It has now been found that compounds of formula I and their pharmaceutically acceptable salts are useful in a variety of pharmaceutical indications.

For example, the compounds according to the invention are useful for the treatment of respiratory disorders in connection with the Chronic Obstructive Pulmonary Disease (COPD).

20

These compounds may also be used for treating symptoms related to disorders such as chronic bronchitis, emphysema, cough, either directly linked to COPD or not, and also cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis and asthma.

25

Preferred compounds have antagonist activity against the human m3 muscarinic receptor at concentrations ranging from 100 nM to almost 1 nM and incorporate activity as selective phosphodiesterase IV (PDE IV) inhibitors at concentrations ranging from 2.5 µM to almost 50 nM. These compounds also recognize the m1, m2, m4 and m5 receptors with variable receptor subtype selectivity.

30

Preferred compounds have been proven to antagonise carbachol-induced contraction of guinea-pig trachea in vitro.

In addition the compounds according to the invention may be used in the treatment of the following symptoms which are related to PDE IV or M₃:

PDE IV-related

35

Amongst PDEs, PDE IV is highly selective for cAMP. Four human PDE IV subtypes have been identified, with distinct tissue and cellular distribution. PDE IVA

appears to be distributed ubiquitously. PDE IVB is expressed in heart, brain, skeletal muscle and lung. PDE IVC is abundant in neuronal tissue but is absent from immune and inflammatory cells. PDE IVD is abundant in immune and inflammatory cells. Functional effects such as those associated with gastric acid secretion, relaxation of the myometrium, bronchorelaxation and diuresis in the kidney have been attributed to the effect of PDE IV inhibition. This argues in favour of the interest of such approach for treating GI disorders, kidney dysfunction, respiratory and inflammatory disorders.

Furthermore, PDE IV may also be of biological significance and therapeutic relevance in CNS therapeutic indications such as depression and dementia. The hypothesis is that enhanced cAMP availability produced by inhibition of PDE IV stimulates the increase in noradrenaline function produced by classical antidepressants such as imipramine at the post-synaptic level (Wachtel H., Pharmacopsychiatry (1990), 23, 27-32). Denbufyline has also been shown to increase cAMP in cortical slices, indicating a potential in the treatment of cognitive impairment (Nicholson C.D., Psychopharmacology (1990), 101, 147-159).

In addition, the PDE IV enzyme may also be a potential target for anticancer therapy, due to its inhibitory effect on tumour cell growth (Drees M., Zimmermann R., Eisenbrand G., Cancer Res. (1993), 53, 3058-3061), and PDE IV inhibition may be beneficial in tissue transplantation (Pinsky D., Oz M., Morris S., J. Clin. Invest. (1993), 92, 2994-3002) and for cardiovascular diseases including atherosclerosis and hypertension (Demouliou-Mason C., Exp. Opin. Ther. Patents (1994), 4, 813-823).

M₃-related

25 Lower urinary tract disorders:

The parasympathetic nervous system is the principal excitatory innervation to the detrusor smooth muscle of the urinary bladder. Acetylcholine, released from postganglionic cholinergic nerves, activates post-junctional muscarinic receptors in the detrusor which causes contraction of the bladder that is coordinated with outlet relaxation and leads to voiding of urine (De Groat W.C., Booth A.M., Yoshimura N., In: "Nervous control of the urogenital system", Maggi, C.A. (Ed), Harwood Academic Publishers, Amsterdam, (1993), 227-290). Both m₂ and m₃ muscarinic receptors are expressed in the smooth muscle of the bladder detrusor (Hegde S.S., Eglen R.M., Life Science (1999), 64, 419-428). Muscarinic m₃ receptors play a key role in mediating the contractile effect of Acetylcholine (ACh) but m₂ receptors may also contribute to micturition through opposing the relaxing effect of adrenergic sympathetic tone. Prejunctional m₁ facilitory muscarinic receptors may also be involved.

Aging, inflammation or irritants and neurological trauma may result in increased nerve afferent and efferent activity and overactive bladder to become a leading cause of trouble presenting some symptoms such as urgency and frequency micturition and incontinence.

5 Therefore, non-selective muscarinic M₃ antagonists have utility in the treatment of bladder disorders including urge and mixed urinary incontinence, pollakiuria, neurogenic or unstable bladder, hyperreflexia and chronic cystitis (Gillberg P.G., Sundquist S., Nilvebrant L., Eur. J. Pharmacol. (1998), 349, 285-292; Schwantes U., Topfmeler P., International Journal of Clinical Pharmacology and Therapeutics (1999), 37, 209-218; Andersson K.E. et al., In: "Incontinence. 1st 10 International Consultation on Incontinence - June 28 - July 1, 1998 - Monaco", Abrams P., Khouri S., Wein A., Les Editions Vingt et Un, Paris, (1999), 447-486).

Gastrointestinal disorders:

15 Contractility of the smooth muscle of the gastrointestinal tract is under the control of parasympathetic tone and Acetylcholine (ACh). Contraction of the intestinal smooth muscle is principally dependent upon activation of muscarinic m₃ receptors although stimulation of m₂ muscarinic receptors might synergize with m₃-mediated responses (Sawyer G.W., Ehlert F.J., J. Pharmacol. Exp. Ther. (1998), 284, 269-277).

20 Gastric secretion is also under the control of the parasympathetic nervous system. Secretagogue effect of ACh depend on the activation of post-junctional m₃ receptors whilst m₁ receptors located on the post-ganglionic nerves of the myenteric plexus have a facilitatory role on the parasympathetic nerve activity.

Therefore, m₃ and m₁ muscarinic receptor antagonists are potentially useful 25 for treating gastrointestinal disorders associated with intestinal hypermotility such as irritable bowel syndrome, spastic colitis and diverticulosis (Wallis R.M., Napier C.M., Life Science (1999), 64, 395-401) and to reduce acid secretion, gastric motility, to aid the healing of peptic ulcers and to treat gastroesophageal reflux disease and stress-related erosive syndrome (Rademaker J.W., Hunt R.H., Scand. J. Gastroenterol. 30 (1990), 25, 19-26; Coruzzi G., Adami M., Bertaccini G., Arch. Int. Pharmacodyn. Ther. (1989), 302, 232-241).

CNS - Cognitive disorders

The release of acetylcholine from central cholinergic nerves is under 35 autoinhibitory control via m₂ or m₄ autoreceptors. Therefore, M₂ or M₄ antagonists might reduce the levels of ACh released and may offer a potential approach for the treatment of cognitive disorders causally related to a deterioration or deficit of cortical cholinergic neurons, such as in senile dementia

and Alzheimer's disease (Doods H.N., Quinrion R., Mihm G., Life Science (1993), 52, 497-503).

CNS - Locomotor disorders

5 The nigrostriatum has many more m₄ receptors than any other tissue (Santiago M.P., Potter L.T., Brain Res. (2001), 894, 12-20). These receptors exert inhibitory control on Dopamine (D1) receptor mediated locomotor stimulation (Gomeza J., Zhang L., Kostenis E., Felder C., Bymaster F., Brodkin J., Shannon H., Xia B., Deng C., Wess J., Proc. Natl. Acad. Sci. USA. (1999), 96, 10483-10488).

10 Therefore, centrally active M₄ muscarinic antagonists may have the potential to treat Parkinsonian's disorders and dyskinesia thought to be causally related to a deterioration of dopaminergic neurons in the nigrostriatum (Salamone J.D., Carlson B.B., Correa M., Wisniecki A., Nisenbaum E., Nisenbaum L., Felder C., In: "Society for Neuroscience 30th Annual Meeting New Orleans, Nov 2000", Mayorga et al., (1999), 15 Abstract 278.5; Mayorga A.J., Cousins M.S., Trevitt J.T., Conlan A., Gianutsos G., Salamone J.D., Eur. J. Pharmacol. (1999), 364, 7-11).

CNS - feeding disorders

20 Activation of muscarinic m₃ receptors located in the lateral hypothalamus contributes to feeding behaviour (Yamada M. et al., Nature (2001), 410, 207-212). Thereby, M₃ antagonists may offer new therapeutic perspectives for the treatment of obesity, bulimia and metabolic syndrome.

CNS - sleeping disorders

25 Activation of m₁ and m₃ receptors in the mediodorsal pontine tegmentum results in a marked increased in paradoxical sleep indicating that centrally active M₃ antagonists can be useful for treating sleep disorders (Imeri L., Bianchi S., Angeli P., Mancia M., Brain Res. (1994), 636, 68-72; Sakai, K., Onoe H., Eur. J. Neurosci. (1997), 9, 415-23).

30 Cardiovascular disorders

The heart rate is under parasympathetic tone via muscarinic m₂ receptors on the SA node.

35 Therefore, m₂ receptor antagonists are of potential value in the emergency treatment of acute myocardial infarction where the dominant autonomic influence of the heart is via the vagus nerve, causing sinus or nodal bradycardia (Van Zwieten P.A., Doods H.N., Cardiovascular Drugs and Therapy (1995), 9, 159-167).

Thus the present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof for use as a medicament.

In a further aspect, the present invention concerns the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of PDE IV and/or M₃ related disorders such as mentioned above.

In particular, the present invention concerns the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of COPD or of symptoms related to disorders such as chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis and asthma.

The present invention also concerns a method for treating COPD or symptoms related to disorders such as chronic bronchitis, emphysema, cough, cystic fibrosis, pulmonary fibrosis, adult respiratory distress syndrome, rhinitis and asthma in a mammal in need of such treatment, comprising administering at least one compound of formula I or a pharmaceutically acceptable salt thereof to a patient.

The term "treatment" as used herein includes curative treatment and prophylactic treatment. By "curative" treatment is meant efficacy in treating a current symptomatic episode of a disorder or condition. By "prophylactic" treatment is meant prevention of the occurrence or recurrence of a disorder or condition.

For treating diseases, compounds of formula I, or their pharmaceutically acceptable salts, may be employed at an effective daily dosage and administered in the form of a pharmaceutical composition.

Therefore, another embodiment of the present invention concerns a pharmaceutical composition comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable diluent or carrier.

To prepare a pharmaceutical composition according to the invention, one or more of the compounds of formula I or a pharmaceutically acceptable salt thereof, is intimately admixed with a pharmaceutical diluent or carrier according to conventional pharmaceutical techniques known to the skilled practitioner.

Pharmaceutical compositions comprising compounds according to the invention can, for example, be administered orally or parenterally, i.e., intravenously, intramuscularly, subcutaneously or by inhalation (orally or intranasally). In a preferred embodiment, the pharmaceutical compositions are administered by inhalation.

Pharmaceutical compositions suitable for oral administration can be solids or liquids and can, for example, be in the form of tablets, pills, dragees, gelatin capsules,

solutions, syrups, aerosols, powders for inhalation and the like. Pharmaceutical compositions suitable for administration by inhalation are preferred.

The following examples are provided for illustrative purposes.

5

Unless otherwise specified in the examples, characterization of the compounds was performed according to the following methods:

NMR spectra are recorded on a BRUKER AC 250 Fourier Transform NMR Spectrometer fitted with an Aspect 3000 computer and a 5 mm $^1\text{H}/^{13}\text{C}$ dual probehead or BRUKER DRX 400 FT NMR fitted with a SG Indigo2 computer and a 5 mm inverse geometry $^1\text{H}/^{13}\text{C}/^{15}\text{N}$ triple probehead. The compound is studied in DMSO-d₆ (or CDCl₃) solution at a probe temperature of 313 K and at concentrations ranging from 2 to 20 mg/ml. The instrument is locked on the deuterium signal of DMSO-d₆ (or CDCl₃). Chemical shifts are given in ppm downfield from TMS taken as internal standard.

Mass spectrometric measurements in LC/MS mode are performed as follows:

HPLC conditions

Analyses are performed using a WATERS Alliance HPLC system mounted with an INERTSIL ODS 3-, DP 5 μm , 250 X 4.6 mm column.

20 The gradient runs from 100 % solvent A (acetonitrile, water, TFA (10/90/0.1, v/v/v)) to 100 % solvent B (acetonitrile, water, TFA (90/10/0.1, v/v/v)) in 7 min with a hold at 100 % B of 4 min. The flow rate is set at 2.5 ml/min and a split of 1/10 is used just before API source. The chromatography is carried out at 30 °C.

25 *MS conditions*
Samples are dissolved in acetonitrile/water, 70/30, v/v at the concentration of about 250 $\mu\text{g}/\text{ml}$. API spectra (+ or -) are performed using a FINNIGAN (San Jose, CA, USA) LCQ ion trap mass spectrometer. APCI source operates at 450 °C and the capillary heater at 160 C. ESI source operates at 3.5 kV and the capillary heater at 210 °C.

30 Mass spectrometric measurements in EI/DIP mode are performed as follows: samples are vaporized by heating the probe from 50 °C to 250 °C in 5 min. EI (Electron Impact) spectra are recorded using a FINNIGAN (San Jose, CA, USA) TSQ 700 tandem quadrupole mass spectrometer. The source temperature is set at 150 °C.

Specific rotation is recorded on a Perkin-Elmer MC241 or MC341 polarimeter.
35 The angle of rotation is recorded at 25 °C on 1 % solutions in MeOH. For some molecules, the solvent is CH₂Cl₂ or DMSO, due to solubility problems.

Water content is determined using a Metrohm microcoulometric Karl Fischer titrator.

Preparative chromatographic separations are performed on silicagel 60 Merck, particle size 15-40 µm, reference 1.15111.9025, using in-house modified Jobin Yvon-type axial compression columns (80 mm i.d.), flow rates between 70 and 150 ml/min. Amount of silicagel and solvent mixtures are as described in individual procedures.

5 Preparative chiral chromatographic separations are performed on a DAICEL Chiralpak AD 20µm, 100*500 mm column using an in-house build instrument with various mixtures of lower alcohols and C5 to C8 linear, branched or cyclic alkanes at ± 350 ml/min. Solvent mixtures are as described in individual procedures.

10 Melting points are determined on a Büchi 535 or 545 Tottoli-type fusionometre, and are not corrected, or by the onset temperature on a Perkin Elmer DSC 7.

Unless specified otherwise in the examples, the compounds are obtained in the neutral form.


15 In the tables, the stereochemical information is contained in the three columns headed 'configuration data'. The second column indicates whether a compound has no stereogenic center (ACHIRAL), is a pure configuration isomer or enantiomer (PURE), a racemate (RAC) or is a mixture of two or more stereoisomers, possibly in unequal proportions (MIXT). The first column contains the stereochemical assignment for each recognised center, following the IUPAC numbering used in the preceding column. A 20 number alone indicates the existence of both configurations at that center. A number followed by 'R' or 'S' indicates the known absolute configuration at that center. A number followed by 'S' indicates the existence of only one but unknown absolute configuration at that center. The letter (A, B, C, D) in front is a way of distinguishing the various configuration isomers, enantiomers or racemates of the same structure.

25 The third column precises the cis or trans isomerism.

In the tables, the melting points are in most cases determined by the onset of the DSC curve. When a visual (fusionometer) melting point is given, the value is between brackets.

30 EXAMPLE 1: Synthesis of amidines of formula VII.


1.1 Synthesis of 2-methylcyclopropanecarbonitrile **1**.



To a suspension of sodium hydride (11 g, 0.28 mol, 60 % in oil, washed two times with n-hexane) in tetrahydrofuran (150 ml) is added diethyl cyanomethylphosphonate (45.5 g, 0.25 mol) over 0.5 h, at room temperature. The mixture is stirred 0.25 h. Propylene oxide (16.3 g, 0.28 mol) is added dropwise at room temperature and the solution is stirred for 1 h then heated at reflux for 4 h. The

mixture is cooled and ammonium chloride (115 g) is added. The solvent is distilled, the residue is poured onto crushed ice and extracted three times with diethyl ether. The combined organic layers are washed with brine, dried over magnesium sulfate, concentrated (atmospheric pressure) and the final residue is distilled under reduced pressure (75 °C, 70 mm Hg) to afford pure 2-methylcyclopropanecarbonitrile **1** (7.5 g, 33 %) as an oil.


1.2 Synthesis of 2-methylcyclopropanecarboximidamide hydrochloride **2**.



Gaseous hydrochloric acid is passed through a solution of 2-methylcyclopropanecarbonitrile **1** (7.5 g, 92 mmol) in ethanol (8.5 ml) at 0 °C until 7 g have been absorbed. The resulting mixture is kept in the refrigerator for 48 h. Ethanol (150 ml) is then added and gaseous ammonia is passed through the solution at -5 °C for 4 h. The solvent is evaporated in vacuo. Hydrochloric acid in diethyl ether (3 N solution, 3 ml) is added and the solution is concentrated and dried in vacuo to afford 2-methylcyclopropanecarboximidamide hydrochloride **2** (6.15 g, 50 %) as a paste that is used without further purification.

EXAMPLE 2: synthesis of 4,6-pyrimidinediol derivatives of formula VI.

2.1 Synthesis of 2-cyclopropyl-5-fluoro-4,6-pyrimidinediol **3**.



Sodium (646 mg, 28 mmol) is dissolved in methanol (50 ml) under a nitrogen atmosphere. Cyclopropanecarboximidamide hydrochloride (3.40 g, 28 mmol) is added in one portion. The mixture is stirred at room temperature for 0.25 h, then filtered upon hyflocel. The filtrate is concentrated in vacuo. This free base is added to a solution of sodium (1.29 g, 56 mmol) in methanol (50 ml) under a nitrogen atmosphere, at room temperature. Diethylfluoromalonate (5 g, 28 mmol) is added and the mixture is stirred at 60 °C for 5 h. The solvent is evaporated and the yellowish solid obtained is dissolved in 60 ml of water. The pH is adjusted at 6 with a 5 N HCl solution and the white precipitate formed is filtered and dried. 2-cyclopropyl-5-fluoro-4,6-pyrimidinediol **3** (3.6 g, 76 %) is obtained as a white powder and used in the next step without further purification.


¹H NMR (250 MHz, DMSO): 0.95 (m, 4H), 1.83 (m, 1H), 12.1 (bs, 2H).

Compounds described in table 1 can be synthesized in an analogous way.

Table 1

4	2-cyclopropyl-4,6-pyrimidinediol	Patent Geigy 1966, NL6513321
5	2-cyclopropyl-5-methyl-4,6-pyrimidinediol	MS ($M^{+}\cdot$): 166
6	5-chloro-2-cyclopropyl-4,6-pyrimidinediol	MS ($M^{+}\cdot$): 187/189
7	2-cyclopropyl-5-methoxy-4,6-pyrimidinediol	MS ($M^{+}\cdot$): 182
8	2-cyclopropyl-5-ethyl-4,6-pyrimidinediol	MS ($M^{+}\cdot$): 180
9	2-(2-methylcyclopropyl)-4,6-pyrimidinediol	1H NMR (250 MHz, DMSO): 0.83 (m, 1H), 1.11 (d, 3H), 1.18 (m, 1H), 1.38 (m, 1H), 1.61 (m, 1H), 5.03 (s, 1H)
10	5-methyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediol	MS (MH^{+}): 181
11	2-(cyclopropylmethyl)-5-methyl-4,6-pyrimidinediol	MS (MH^{+}): 181
12	2-cyclobutyl-5-methyl-4,6-pyrimidinediol	MS ($M^{+}\cdot$): 180
13	2-isopropyl-5-methyl-4,6-pyrimidinediol	MS (MH^{+}): 169
14	2-cyclopentyl-5-methyl-4,6-pyrimidinediol	MS ($M^{+}\cdot$): 194
15	[3-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-propyl]-carbamic acid <i>tert</i> -butyl ester	MS (MH^{+}): 310
16	[4-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-butyl]-carbamic acid <i>tert</i> -butyl ester	MS (MH^{+}): 324

5 2.2 Synthesis of 2-cyclopropyl-5-nitro-4,6-pyrimidinediol **17**.




Glacial acetic acid (90 ml) is added to fuming nitric acid (40 ml) at 0 °C. The solution is warmed to 30 °C and 2-cyclopropyl-4,6-pyrimidinediol **4** (35 g, 0.25 mol) is added in portions. The temperature is kept between 30 and 40 °C. After 1h, the mixture is poured onto crushed ice and filtered. The filtrate is concentrated to 50 ml in vacuo. Methanol is added and the precipitate is filtered and dried. Pure 2-cyclopropyl-5-nitro-4,6-pyrimidinediol **17** (39.8 g, 81 %) is obtained and used in the next step without further purification.

MS ($M^{+}\cdot$): 197.

10 EXAMPLE 3: synthesis of 4,6-dichloropyrimidine derivatives of formula IV.

3.1 Synthesis of 4,6-dichloro-2-cyclopropyl-5-fluoropyrimidine **18**:



15 2-cyclopropyl-5-fluoro-4,6-pyrimidinediol **3** (3.51 g, 21 mmol) is suspended in phosphorus oxychloride (15 ml). A mixture of N,N-diethylaniline (3.08 g, 21 mmol) and phosphorus oxychloride (15 ml) is added dropwise to the suspension at 0 °C. The resulting mixture is stirred at 110 °C for 2 h, then cooled to room temperature. The brown solution is poured onto crushed ice and extracted five times with dichloromethane. The combined organic layers are washed three times with a 1 N HCl solution, dried over magnesium sulfate and concentrated in vacuo to afford 4,6-dichloro-2-cyclopropyl-5-fluoropyrimidine **18** as an orange oil (4.80 g, 100 %) which is used in the next step without further purification.

20 MS ($M^{+}\cdot$): 205/207/209.

Compounds described in table 2 can be synthesized in an analogous way.


Table 2

19	4,6-dichloro-2-cyclopropylpyrimidine	MS (M^+): 189/191/193
20	4,6-dichloro-2-cyclopropyl-5-methylpyrimidine	MS (M^+): 202/204/206
21	4,5,6-trichloro-2-cyclopropylpyrimidine	MS (M^+): 222/224/226
22	4,6-dichloro-2-cyclopropyl-5-pyrimidinyl methyl ether	MS (M^+): 218/220/222
23	4,6-dichloro-2-cyclopropyl-5-ethylpyrimidine	1H NMR (250 MHz, CDCl ₃): 1.12 (m, 4H), 1.20 (t, 3H), 2.16 (m, 1H), 2.85 (q, 2H)
24	4,6-dichloro-2-(2-methylcyclopropyl)pyrimidine	eb. = 85°C/1 mmHg
25	4,6-dichloro-5-methyl-2-(2-methylcyclopropyl)pyrimidine	MS (M^+): 216/218/220
26	4,6-dichloro-2-(cyclopropylmethyl)-5-methylpyrimidine	MS (MH ⁺): 217/219/221
27	4,6-dichloro-2-cyclobutyl-5-methylpyrimidine	MS (MH ⁺): 216/218/220
28	4,6-dichloro-2-cyclopropyl-5-nitropyrimidine	MS (M^+): 233/235/237
29	4,6-dichloro-2-isopropyl-5-methylpyrimidine	MS (M^+): 204/206/208
30	4,6-dichloro-2-cyclopentyl-5-methylpyrimidine	MS (M^+): 230/232/234

EXAMPLE 4: synthesis of compounds of formula II and II-A.

4.1 Synthesis of 6-chloro-N,2-dicyclopropyl-5-fluoro-4-pyrimidinamine **31**.

5



Cyclopropylamine (11.4 g, 0.200 mol) is added to 4,6-dichloro-2-cyclopropyl-5-fluoropyrimidine **18** (4.80 g, 23 mmol) and the solution is stirred at room temperature for 1 h. The mixture is diluted with diethylether, washed two times with a saturated sodium bicarbonate solution. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo to afford 6-chloro-N,2-dicyclopropyl-5-fluoro-4-

pyrimidinamine **31** as a yellow oil (4.99 g, 95 %) which is used in the next step without further purification.

MS ($M^{+}\cdot$): 227/229.

5 Compounds described in table 3 can be synthesized in an analogous way.


Table 3

32	6-chloro-N,2-dicyclopropyl-4-pyrimidinamine	MS (MH ⁺): 210/212
33	6-chloro-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	MS (MH ⁺): 223/225
34	5,6-dichloro-N,2-dicyclopropyl-4-pyrimidinamine	MS (MH ⁺): 244/246/248
35	6-chloro-N,2-dicyclopropyl-5-methoxy-4-pyrimidinamine	MS (MH ⁺): 240/242
36	6-chloro-N,2-dicyclopropyl-5-ethyl-4-pyrimidinamine	MS (MH ⁺): 238/240
37	N-[6-chloro-2-(2-trans-methylcyclopropyl)-4-pyrimidinyl]-N-cyclopropylamine ⁽ⁱ⁾	MS (MH ⁺): 224/226
38	N-[6-chloro-2-(2-trans-methylcyclopropyl)-4-pyrimidinyl]-N-cyclopropylamine	MS (MH ⁺): 224/226 [α] _D ²⁵ = +87,28 (c=1, CH ₂ Cl ₂)
39	N-[6-chloro-2-(2-trans-methylcyclopropyl)-4-pyrimidinyl]-N-cyclopropylamine	MS (MH ⁺): 224/226 [α] _D ²⁵ = -83,80 (c=1, CH ₂ Cl ₂)
40	6-chloro-N-cyclopropyl-5-methyl-2-(2-trans-methylcyclopropyl)-4-pyrimidinamine	MS (MH ⁺): 238/240
41	6-chloro-N-cyclopropyl-5-methyl-2-(2-cis-methylcyclopropyl)-4-pyrimidinamine	MS (MH ⁺): 238/240
42	N-[6-chloro-2-(cyclopropylmethyl)-5-methyl-4-pyrimidinyl]-N-cyclopropylamine	MS (MH ⁺): 238/240
43	6-chloro-2-cyclobutyl-N-cyclopropyl-5-methyl-4-pyrimidinamine	MS (MH ⁺): 237/239
44	6-chloro-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine	MS (MH ⁺): 255/257
45	6-chloro-N-cyclobutyl-2-cyclopropyl-5-methyl-4-pyrimidinamine	MS (MH ⁺): 238/240
46	6-chloro-N-cyclopropyl-2-isopropyl-5-methyl-4-pyrimidinamine	MS (MH ⁺): 226/228
47	6-chloro-2-cyclopentyl-N-cyclopropyl-5-methyl-4-pyrimidinamine	MS (MH ⁺): 252/254
158	6-chloro-2-cyclopropyl-5-methyl-N-(2-methylcyclopropyl)-4-pyrimidinamine	MS (MH ⁺): 238/240
159	6-chloro-2-cyclopropyl-5-methyl-N-(1-methylcyclopropyl)-4-pyrimidinamine	MS (MH ⁺): 238/240
160	6-chloro-2-cyclopropyl-5-methyl-N-(2-phenylcyclopropyl)-4-pyrimidinamine	MS (MH ⁺): 300/302

(i) compound **37** was resolved into its enantiomers **38** (first eluted) and **39** (second eluted) by chromatography on a chiral support (Daicel Chiraldpak AD, isopropanol/n-hexane 1/99, 20 °C).

5 4.2 Synthesis of 4-chloro-2-cyclopropyl-6-(3-fluoro-azetidin-1-yl)-pyrimidine **163**.


4.2.1 Synthesis of 1-benzhydryl-3-fluoroazetidine **161**.



A solution of N-tetrabutylammonium fluoride (1 M solution in THF, 32 ml, 32 mmol) is added dropwise to a solution of methanesulfonic acid 1-benzhydryl-azetidin-
10 3-yl ester (10.75 g, 32 mmol) in acetonitrile (250 ml). The solution is refluxed for 30 hours then concentrated in vacuo. The mixture is diluted with dichloromethane and washed two times with water. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo to afford 10.5 g of a crude mixture which is purified
15 by column chromatography (dichloromethane/hexane 3/1) to afford pure 1-benzhydryl-3-fluoroazetidine **161** (4.3 g, 55 %).

MS (MH⁺): 242.


4.2.2 Synthesis of 3-fluoroazetidine hydrochloride **162**.



Palladium on barium sulfate (5 %, 1.5 g) is suspended in methanol (20 ml)
20 under a nitrogen atmosphere. 1-benzhydryl-3-fluoroazetidine **161** (4.3 g, 18 mmol) is added together with water (0.6 ml), methanol (80 ml) and a 3 N hydrochloric acid-methanol solution (16 ml). The mixture is put under a 50 psi hydrogen pressure and heated at 55 °C for 3 days. The catalyst is filtered and the filtrate is concentrated in vacuo. The mixture is diluted with water and washed three times with hexane. The combined aqueous layers are concentrated in vacuo to afford 3-fluoroazetidine hydrochloride **162** (2.1 g, 99 %) which is used in the next step without further purification.
25

MS (MH⁺): 76.

4.2.3 Synthesis of 4-chloro-2-cyclopropyl-6-(3-fluoro-azetidin-1-yl)-pyrimidine 163.



A mixture of 4,6-dichloro-2-cyclopropylpyrimidine **19** (1.05 g, 5.5 mmol), 3-fluoroazetidine hydrochloride **162** (0.68 g, 6 mmol) and potassium carbonate (2.48 g, 18 mmol) in 1-methoxy-2-propanol (10 ml) is heated at 65°C for 2 hours. The mixture is cooled, concentrated in vacuo, diluted with dichloromethane and washed three times with water. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo to afford 4-chloro-2-cyclopropyl-6-(3-fluoro-azetidin-1-yl)-pyrimidine **163** (1.16 g, 92 %) as a yellow oil which is used in the next step without further purification.


MS (MH⁺): 228/230.

Compounds described in table 4 can be synthesized according to this method.

Table 4:

	IUPAC NAME	MS (LC-MS)
164	4-(1-azetidinyl)-6-chloro-2-cyclopropyl-5-methylpyrimidine	224/226
165	4-(1-azetidinyl)-6-chloro-2-cyclopropylpyrimidine	210/212
166	4-chloro-2-cyclopropyl-5-methyl-6-(3-methyl-1-azetidinyl)pyrimidine	238/240
167	4-chloro-2-cyclopropyl-6-(3-methyl-1-azetidinyl)pyrimidine	224/226
168	4-chloro-2-cyclopropyl-6-(3,3-dimethyl-1-azetidinyl)-5-methylpyrimidine	252/254
169	1-(6-chloro-2-cyclopropyl-5-methyl-4-pyrimidinyl)-3-azetidinol	240/242
170	4-chloro-2-cyclopropyl-6-(3-fluoro-1-azetidinyl)-5-methylpyrimidine	242/244
171	4-chloro-2-cyclopropyl-6-(3-methoxy-1-azetidinyl)-5-methylpyrimidine	254/256


EXAMPLE 5: synthesis of 4-hydroxypyrimidines of formula XII

5.1 Synthesis of 2-cyclopropyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-ol **48**.

Sodium (0.417 g, 18.1 mmol) is dissolved in methanol (65 ml) under a nitrogen atmosphere. Cyclopropanecarboximidamide hydrochloride (2.19 g, 18.1 mmol) is added in one portion. The mixture is stirred at room temperature for 0.25 h, then filtered upon hyflocel. The filtrate is concentrated in vacuo to 30 ml. This free base is added to a solution of sodium (0.834 g, 36.2 mmol) in methanol (130 ml) under a nitrogen atmosphere, at room temperature. 2-ethoxy-4,5-dihydro-3*H*-pyrrole-3-carboxylic acid ethyl ester (3.4 g, 18.1 mmol) in methanol is added and the mixture is stirred at 60 °C overnight. After cooling, the solvent is evaporated and the solid obtained is dissolved in water. The pH is adjusted at 5 with a 5 N HCl solution and the white precipitate formed is filtered and dried. 2-cyclopropyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-ol **48** (1.88 g, 59 %) is obtained as a white powder and used in the next step without further purification.

MS (MH⁺): 178.

EXAMPLE 6: synthesis of 4-chloropyrimidines of formula X.

6.1 Synthesis of 4-chloro-2-cyclopropyl-5,6,7,8-tetrahydro-5*H*-pyrido[2,3-*d*]pyrimidine **50**.

[3-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-propyl]-carbamic acid *tert*-butyl ester **15** (1.4 g, 4.5 mmol) is suspended in phosphorus oxychloride (10 ml). A mixture of N,N-diethylaniline (0.744 g, 5 mmol) and phosphorus oxychloride (10 ml) is added dropwise to the suspension at room temperature. The resulting mixture is stirred at 100 °C overnight. The solution is poured onto crushed ice and extracted two times with dichloromethane. The aqueous layer is alkalinized using a saturated sodium hydrogenocarbonate solution (pH 8), extracted two times with dichloromethane, reacidified using HCl 5N (pH 3) and extracted again with dichloromethane. The combined aqueous layers are alkalinized (pH 10) and the white


precipitate formed is filtered and dried. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo to afford a mixture of 4-chloro-2-cyclopropyl-5,6,7,8-tetrahydro-5*H*-pyrido[2,3-*d*]pyrimidine **50** and non-cyclized 3-(4,6-dichloro-2-cyclopropyl-pyrimidin-5-yl)propylamine **49**. This mixture is dissolved in 1-methoxy-2-propanol and heated at 140 °C for 5 h. After cooling, the solution is diluted with dichloromethane and washed with water (2x) and with an hydrochloric acid solution (1 N). The combined organic layers are dried over magnesium sulfate and concentrated in vacuo. The resulting crude mixture is purified by chromatography on silica gel preparative plates (dichloromethane/ethanol/ammonia 97/3/0.3) to afford a solid, which is combined with the first-formed precipitate. Pure 4-chloro-2-cyclopropyl-5,6,7,8-tetrahydro-5*H*-pyrido[2,3-*d*]pyrimidine **50** is obtained as an orange solid (209 mg, 20 %).

MS (MH⁺): 210/212.

15 4-chloro-2-cyclopropyl-6,7,8,9-tetrahydro-5*H*-pyrimido[4,5-*b*]azepine **51** can be synthesized in an analogous way.

MS (MH⁺): 224/226

20 6.2 Synthesis of 4-chloro-2-cyclopropyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine **52**.




25 2-cyclopropyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-ol **48** (0.5 g, 2.8 mmol) is suspended in phosphorus oxychloride (0.7 ml). A mixture of N,N-diethylaniline (0.46 g, 3.1 mmol) and phosphorus oxychloride (0.7 ml) is added dropwise to the suspension at room temperature. The resulting mixture is stirred at 120 °C for 3 h. The solution is poured onto crushed ice and extracted two times with dichloromethane. The aqueous layer is alkalinized (pH 10) and extracted four times with dichloromethane. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo. The crude mixture (370 mg, 68 %, 91 % purity) is used in the next step without further purification due to the instability of the compound.

30 MS (MH⁺): 196/198


EXAMPLE 7: synthesis of compounds of formula I.

7.1 Synthesis of N,2-dicyclopropyl-5-fluoro-6-(4-thiomorpholiny)-4-pyrimidinamine **120**.




5 A mixture of thiomorpholine (2.27 g, 22 mmol) and 6-chloro-N,2-dicyclopropyl-5-fluoro-4-pyrimidinamine **31** (1 g, 4.4 mmol) is stirred at 110 °C for 18 hours. After cooling, the brown solution is diluted with dichloromethane, washed two times with a saturated sodium bicarbonate solution. The combined organic layers are dried over magnesium sulfate and concentrated under high vacuum to afford a brown oil. The
10 crude oil is purified by column chromatography (hexane/ethyl acetate: 80/20) to give N,2-dicyclopropyl-5-fluoro-6-(4-thiomorpholiny)-4-pyrimidinamine **120** (915 mg, 71 %) as a yellowish solid.

7.2 Synthesis of N⁴-cyclohexyl-N⁶,2-dicyclopropyl-5-methyl-4,6-pyrimidinediamine **141**.



20 A mixture of cyclohexylamine (1.78 g, 18 mmol) and 6-chloro-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine **33** (0.70 g, 3 mmol) in 1-methoxy-2-propanol (2 ml) is stirred at 125 °C for 120 hours. After cooling, the brown solution is diluted with dichloromethane, washed two times with a saturated sodium bicarbonate solution. The combined organic layers are dried over magnesium sulfate and concentrated under high vacuum to afford a brown oil. The crude oil is purified by column chromatography (dichloromethane/methanol: 97.3/2.7) to give pure N⁴-cyclohexyl-N⁶,2-dicyclopropyl-5-methyl-4,6-pyrimidinediamine **141** (0.150 g, 17 %).

7.3 Synthesis of 6-(1-azepanyl)-N⁴,2-dicyclopropyl-4,5-pyrimidinediamine 63.




6-(1-azepanyl)-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine **197** was synthesized as described in 7.1 using 6-chloro-N,2-dicyclopropyl-5-nitro-4-pyridinamine **44** and azepane as starting material.

MS (M⁺): 318.


To a suspension of 6-(1-azepanyl)-N,2-dicyclopropyl-5-nitro-4-pyrimidinamine **197** (0.5 g, 16 mmol) in 1,4-dioxane (35 ml) and water (35 ml) is added sodium hydrosulfite (2.19 g, 13 mmol) and ammonia (25 % solution, 1.2 ml). The mixture is stirred at room temperature for 10 h then diluted with ethyl acetate and washed three times with water. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo to afford a yellow oil. The crude oil is purified by column chromatography (dichloromethane/ethanol/ammonia: 95/5/0.5) to give pure 6-(1-azepanyl)-N⁴,2-dicyclopropyl-4,5-pyrimidinediamine **63** (137 mg, 30 %) as a reddish solid.

7.4 Synthesis of 1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinone hydrate 107.




20 A solution of 1 N HCl (15 ml) is added to a solution of N,2-dicyclopropyl-6-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-5-methyl-4-pyrimidinamine **149** (285 mg, 0.86 mmol) in tetrahydrofuran (15 ml). The mixture is stirred at room temperature for 18 h, then diluted with dichloromethane and washed three times with sodium bicarbonate. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo to afford a white paste. The compound is dried under vacuum to give pure 1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinone hydrate **107** (160 mg, 61 %) as a white paste.

7.5 Synthesis of 6-azepan-1-yl-5-bromo-N,2-dicyclopropylpyrimidin-4-amine 61.



N-Bromosuccinimide (0.39 g, 2.2 mmol) is added to a solution of 6-(1-azepanyl)-N,2-dicyclopropyl-4-pyrimidinamine **62** (0.5 g, 1.84 mmol) in chloroform (2 ml). The mixture is stirred at 60 °C overnight then cooled, diluted with dichloromethane and washed two times with water. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo. The crude mixture is purified by column chromatography (dichloromethane/ethanol: 97/3) to give pure 6-azepan-1-yl-5-bromo-N,2-dicyclopropylpyrimidin-4-amine **61** (134 mg, 21 %) as a brownish paste.


7.6 Synthesis of 4-azepan-1-yl-2-cyclopropyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine 155.



A mixture of azepane (18.2 ml, 142 mmol) and 4-chloro-2-cyclopropyl-5,6,7,8-tetrahydro-5H-pyrido[2,3-d]pyrimidine **50** (0.851 g, 4.06 mmol) is stirred four days at 110 °C. After cooling, the brown solution is diluted with dichloromethane and washed two times with water. The combined organic layers are dried over magnesium sulfate and concentrated under high vacuum to afford a brown oil. The crude oil is purified by column chromatography (dichloromethane/ethanol/ammonia: 90/10/1) to give pure 4-azepan-1-yl-2-cyclopropyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine **155** as a brown solid.

7.7 Synthesis of 1-[2-cyclopropyl-6-(3-fluoro-azetidin-1-yl)-pyrimidin-4-yl]azepane fumarate (3:2) **195.**

43




A mixture of hexamethyleneimine (2.87 g, 29 mmol) and 4-chloro-2-cyclopropyl-6-(3-fluoro-azetidin-1-yl)-pyrimidine **163** (1.1 g, 4.8 mmol) in 1-methoxy-2-propanol (2 ml) is stirred at 110 °C for 6 hours. After cooling, the solution is diluted with dichloromethane, washed two times with a saturated sodium bicarbonate solution. The combined organic layers are dried over magnesium sulfate and concentrated under high vacuum to afford a brown oil (2.15 g). The crude oil is purified by column chromatography (dichloromethane/methanol 99.5/0.5) to give pure 1-[2-cyclopropyl-6-(3-fluoro-azetidin-1-yl)-pyrimidin-4-yl]azepane (1 g, 72 %).

MS (MH⁺): 291.

A solution of fumaric acid (0.6 g) in isopropanol (4 ml) is added to a solution of 1-[2-cyclopropyl-6-(3-fluoro-azetidin-1-yl)-pyrimidin-4-yl]azepane in diisopropyl ether (10 ml). The mixture is triturated, then filtered, recrystallized from diisopropyl ether and dried in vacuo to afford pure 1-[2-cyclopropyl-6-(3-fluoro-azetidin-1-yl)-pyrimidin-4-yl]azepane fumarate (3:2) **195** (1.2 g, 58 %).

MS (MH⁺): 291.

7.8 Synthesis of methanesulfonic acid 1-(6-azepan-1-yl-2-cyclopropyl-5-methyl-pyrimidin-4-yl)-azetidin-3-yl ester **190**.




A solution of methanesulfonyl chloride (0.63 ml, 7.6 mmol) in dichloromethane (10 ml) is added dropwise to a solution of 1-(6-azepan-1-yl-2-cyclopropyl-5-methyl-pyrimidin-4-yl)-azetidin-3-ol **189** (1.90 g, 6.3 mmol) and triethylamine (1.74 ml, 13 mmol) in dichloromethane (90 ml) at 0 °C. The mixture is stirred 1 hour at 0 °C and 1 hour at room temperature. Water (40 ml) is added and the mixture is extracted three times with dichloromethane. The combined organic layers are dried over magnesium

sulfate and concentrated in vacuo to afford pure methanesulfonic acid 1-(6-azepan-1-yl-2-cyclopropyl-5-methyl-pyrimidin-4-yl)-azetidin-3-yl ester **190** (2.66 g, 100 %).

MS (MH^+): 381.


5 7.9 Synthesis of 1-[6-(3-bromo-azetidin-1-yl)-2-cyclopropyl-5-methyl-pyrimidin-4-yl]-azepane **182**.



A mixture of methanesulfonic acid 1-(6-azepan-1-yl-2-cyclopropyl-5-methyl-pyrimidin-4-yl)-azetidin-3-yl ester **190** (0.4 g, 1 mmol) and sodium bromide (0.103 g, 1 mmol) in N,N-dimethylformamide (10 ml) is heated at 100 °C for 6 days. The mixture is then cooled and concentrated in vacuo. The mixture is diluted with dichloromethane and washed two times with water. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo to afford 0.4 g of a crude mixture, which is purified by column chromatography (dichloromethane/methanol 98/2). 1-[6-(3-bromo-azetidin-1-yl)-2-cyclopropyl-5-methyl-pyrimidin-4-yl]-azepane **182** (0.11 g, 30 %) is obtained.

MS (MH^+): 365/367.

20 7.10 Synthesis of 1-(6-azepan-1-yl-2-cyclopropyl-5-methyl-pyrimidin-4-yl)-azetidine-3-carbonitrile **183**.




A mixture of methanesulfonic acid 1-(6-azepan-1-yl-2-cyclopropyl-5-methyl-pyrimidin-4-yl)-azetidin-3-yl ester **190** (0.3 g, 0.8 mmol) and sodium cyanide (0.047 g, 1.0 mmol) in N,N-dimethylformamide (5 ml) is heated at 120°C for 24 hours. The mixture is then cooled and concentrated in vacuo. The mixture is diluted with dichloromethane and washed two times with water. The combined organic layers are

dried over magnesium sulfate and concentrated in vacuo to afford 0.4 g of a crude mixture, which is purified by column chromatography (dichloromethane/ethanol 98/2). 0.10 g (60 %) of 1-(6-azepan-1-yl-2-cyclopropyl-5-methyl-pyrimidin-4-yl)-azetidine-3-carbonitrile **183** is obtained.

5 MS (MH⁺): 312.

7.11 Synthesis of 1-(6-azepany-1-yl-2-cyclopropyl-5-methyl-pyrimidin-4-yl)-azetidin-3-one **193**.



10 A solution of sulfur trioxide / pyridine complex (1.4 g, 8.8 mmol) in DMSO (3.5 ml) is added dropwise to a solution of 1-(6-azepany-1-yl-2-cyclopropyl-5-methyl-pyrimidin-4-yl)-azetidine-3-ol **189** (0.3 g, 0.7 mmol) and triethylamine (1 ml) in DMSO (7 ml). The mixture is stirred at room temperature for 24 hours, poured onto ice, diluted with ethyl acetate and washed two times with water. The combined organic layers are dried over magnesium sulfate and concentrated in vacuo to afford 0.4 g (96 %) of pure 1-(6-azepany-1-yl-2-cyclopropyl-5-methyl-pyrimidin-4-yl)-azetidin-3-one hydrate **193**.

15

MS (MH⁺): 319.

20 Compounds described in table 5 can be synthesized according to one of these methods.

Table 5

Salt/solvate		Configuration data	Free base IUPAC NAME		MH ⁺ (M ⁺)	DSC °C (mp)	alpha _D
53	1 HCl	achiral	N,2-dicyclopropyl-6-(1,3-thiazolidin-3-yl)-4-pyrimidinamine		(262)	181.3	
54	1 HCl	achiral	N-cyclopropyl-2-isopropyl-6-[1,3-thiazolidin-3-yl]-4-pyrimidinamine		(264)	204.4	
55	1 maleate	achiral	6-(1-azepanyl)-2-cyclobutyl-N-cyclopropyl-5-methyl-4-pyrimidinamine	301			
56	1 maleate	achiral	6-(1-azepanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	287			
57	3/2 fumarate	achiral	6-(1-azepanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	287		149.9	
58	1 maleate	achiral	6-(1-azepanyl)-N-cyclobutyl-2-cyclopropyl-5-methyl-4-pyrimidinamine	301			
59	1 maleate	achiral	6-(1-azepanyl)-5-chloro-N,2-dicyclopropyl-4-pyrimidinamine	307		85.2	
60	1 maleate	achiral	6-(1-azepanyl)-N,2-dicyclopropyl-5-fluoro-4-pyrimidinamine	291		111.2	
61		achiral	6-azepan-1-yl-5-bromo-N,2-dicyclopropyl-4-pyrimidinamine	351/353			
62		achiral	6-(1-azepanyl)-N,2-dicyclopropyl-4-pyrimidinamine	273		124.6	
63		achiral	6-(1-azepanyl)-N ⁴ ,2-dicyclopropyl-4,5-pyrimidinediamine	288		(76.9)	
64	1 maleate	achiral	6-(1-azepanyl)-N-cyclopropyl-2-isopropyl-5-methyl-4-pyrimidinamine	289			
65	1 maleate	A-1,2	rac	trans 6-(1-azepanyl)-N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-4-pyrimidinamine	301		
66	1 maleate	B-1,2	rac	cis 6-(1-azepanyl)-N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-4-pyrimidinamine	301		

Salt/solvate		Configuration data	Free base IUPAC NAME	MH ⁺ (M ⁺)	DSC °C (mp)	alphaD
67	B-18,28	pure trans	6-(1-azepanyl)-N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-4-pyrimidinamine	301		-58.79
68	A-18,28	pure trans	6-(1-azepanyl)-N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-4-pyrimidinamine	301		+57.65
69	1 maleate	achiral	6-(1-azepanyl)-N-cyclopropyl-2-(cyclopropylmethyl)-5-methyl-4-pyrimidinamine	301		
70		A-1,2 rac	trans 6-(1-azepanyl)-5-chloro-N-cyclopropyl-2-(2-methylcyclopropyl)-4-pyrimidinamine	321		
71		A-1,2 rac	trans 6-(1-azepanyl)-N-cyclopropyl-2-(2-methylcyclopropyl)-4-pyrimidinamine	287		
72	0.2 iPrOH, 1 maleate	achiral	6-(1-azocanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	301		
73		A-1,2 rac	trans 6-(1-azocanyl)-N-cyclopropyl-2-(2-methylcyclopropyl)-4-pyrimidinamine	301	108.5	
74		3,5 mixt	N,2-dicyclopropyl-6-(3,5-dimethyl-1-piperidiny)-5-methyl-4-pyrimidinamine	301	91.2	
75	1 maleate	achiral	N,2-dicyclopropyl-6-[4-(2-methoxyphenyl)-1-piperidiny]-5-methyl-4-pyrimidinamine	379	123.6	
76	1 iPrOH, 1 maleate	achiral	{1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinyl}(diphenyl)methanol	455	86.1	
77		achiral	N,2-dicyclopropyl-5-methyl-6-[4-(trifluoromethyl)piperidin-1-yl]-4-pyrimidinamine	341	(86.4)	

Salt/solvate	Configuration data	Free base IUPAC NAME	MH ⁺ (M ⁺)	DSC °C (mp)	alphaD
78 1 maleate	achiral	N,2-dicyclopropyl-6-(4,4-difluoro-1-piperidiny)-5-methyl-4-pyrimidinamine	309	121.9	
79	achiral	N,2-dicyclopropyl-6-(4,4-dimethyl-1-piperidiny)-5-methyl-4-pyrimidinamine	301		
80 1 HCl	achiral	N,2-dicyclopropyl-6-(4,4-dimethyl-1-piperidiny)-5-methyl-4-pyrimidinamine	301		
81	achiral	1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinecarboxamide	316	230.6	
82 1 maleate	achiral	6-(4-benzyl-1-piperidiny)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	363	132.1	
83	achiral	1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinecarboxylic acid	317	219.6	
84	achiral	1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-phenyl-4-piperidinecarbonitrile	374	145.3	
85 1 maleate	achiral	ethyl 1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinecarboxylate	345	118.9	
86	achiral	N,2-dicyclopropyl-6-(4-ethyl-1-piperidiny)-5-methyl-4-pyrimidinamine	301		
87 1 HCl	achiral	N,2-dicyclopropyl-6-(4-ethyl-1-piperidiny)-5-methyl-4-pyrimidinamine	301		
88	achiral	N,2-dicyclopropyl-6-(4-ethyl-4-methyl-1-piperidiny)-5-methyl-4-pyrimidinamine	315		

Salt/solvate		Configuration data	Free base IUPAC NAME	MH ⁺ [M ⁺]	DSC °C (mp)	alpha/D
89	1 HCl	achiral	N,2-dicyclopropyl-6-(4-ethyl-4-methyl-1-piperidinyl)-5-methyl-4-pyrimidinamine	315		
90		achiral	1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinol	289	150.0	
91		achiral	1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-phenyl-4-piperidinol	365		
92		achiral	1-[2-cyclopropyl-6-(cyclopropylamino)-5-fluoro-4-pyrimidinyl]-4-phenyl-4-piperidinol	369		
93		achiral	{1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinyl}-4-piperidinylmethanol	303	113.9	
94	1 maleate	achiral	N,2-dicyclopropyl-5-ethyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	301		
95	1 maleate	achiral	N,2-dicyclopropyl-5-methyl-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	287	97.9	
96		achiral	N,2-dicyclopropyl-5-fluoro-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	291		
97	A-1,2	rac	trans N-cyclopropyl-5-methyl-2-(2-methylecyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	301	91.3	
98	1 maleate	B-1,2	cis N-cyclopropyl-5-methyl-2-(2-methylecyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	301		
99	A-18,28	pure	trans N-cyclopropyl-5-methyl-2-(2-methylecyclopropyl)-6-(4-methyl-1-piperidinyl)-4-pyrimidinamine	301		61.65

Salt/solvate	Configuration data	Free base IUPAC NAME	MH ⁺ (M ⁺)	DSC °C (mp)	alphaD
100	B-1§,2§ pure	trans N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidiny)-4-pyrimidinamine	301		-63.51
101	A-1,2 rac	trans N-cyclopropyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidiny)-4-pyrimidinamine	287	120.3	
102	1 HCl	rac	trans N-cyclopropyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidiny)-4-pyrimidinamine	287	148.1
103	1 maleate	rac	trans N-cyclopropyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidiny)-4-pyrimidinamine	287	132.1
104	A-1§,2§ pure	trans N-cyclopropyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidiny)-4-pyrimidinamine	287		65.61
105	B-1§,2§ pure	trans N-cyclopropyl-2-(2-methylcyclopropyl)-6-(4-methyl-1-piperidiny)-4-pyrimidinamine	287		-70.6
106	1 HCl	achiral	N,2-dicyclopropyl-5-methyl-6-(4-methylene-1-piperidiny)-4-pyrimidinamine	285	
107	1 H ₂ O	achiral	1-[2-cyclopropyl-6-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-4-piperidinone	305	
108		achiral	N ⁴ ,2-dicyclopropyl-N ⁶ ,5-dimethyl-N ⁶ -[2-(2-thienyl)ethyl]-4,6-diprimidinediamine	329	
109	1 maleate	achiral	N ⁴ ,2-dicyclopropyl-5-methyl-1-N ⁶ -[2-(2-thienyl)ethyl]-4,6-diprimidinediamine	315	129.1
110	1 maleate	achiral	N ⁴ ,2-dicyclopropyl-N ⁶ -[2-furylmethyl]-N ⁶ ,5-dimethyl-4,6-diprimidinediamine	299	

Salt/solvate	Configuration data	Free base IUPAC NAME	MH ⁺ (M ⁺)	DSC °C (mp)	alphaD
111 1 maleate	achiral	N ⁴ ,2-dicyclopropyl-5-methyl-N ⁶ -(2-thienylmethyl)-4,6-pyrimidinediamine	301	151.9	
112 1 maleate	achiral	N,2-dicyclopropyl-6-(3,6-dihydro-1(2H)-pyridinyl)-5-methyl-4-pyrimidinamine	271	118.9	
113	A-1,2 rac	N-cyclopropyl-6-(3,6-dihydro-1(2H)-pyridinyl)-2-(2-methylcyclopropyl)-4-pyrimidinamine	271	107.4	
114 1 HCl	A-1,2 rac	N-cyclopropyl-6-(3,6-dihydro-1(2H)-pyridinyl)-2-(2-methylcyclopropyl)-4-pyrimidinamine	271		
115 1 maleate	achiral	6-(3-azabicyclo[3.2.1]oct-3-yl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	299		
116 1 maleate	achiral	N ⁴ ,2-dicyclopropyl-5-methyl-N ⁶ -(4-pyridinylmethyl)-4,6-pyrimidinediamine	296	165.3	
117 2 maleate	A-1,2 rac	N ⁴ -cyclopropyl-2-(2-methylcyclopropyl)-N ⁶ -(4-pyridinylmethyl)-4,6-pyrimidinediamine	296		
118 1 maleate	achiral	N,2-dicyclopropyl-5-ethyl-6-(4-thiomorpholiny)-4-pyrimidinamine (1:1)	305	99.5	
119 1 HCl	achiral	N,2-dicyclopropyl-5-methyl-6-(4-thiomorpholiny)-4-pyrimidinamine	(290)	224.4	
120	achiral	N,2-dicyclopropyl-5-fluoro-6-(4-thiomorpholiny)-4-pyrimidinamine	295	(87)	
121	achiral	N,2-dicyclopropyl-6-(4-thiomorpholiny)-4-pyrimidinamine	(276)		

Salt/solvate		Configuration data	Free base IUPAC NAME	MH ⁺ (M ⁺)	DSC °C (mp)	alphaD
122		achiral	N,2-dicyclopropyl-5-methoxy-6-(4-thiomorpholiny)-4-pyrimidinamine	307		
123	1 maleate	achiral	N-cyclopropyl-2-isopropyl-5-methyl-6-(4-thiomorpholiny)-4-pyrimidinamine	293	89.64	
124	1 HCl	A-1§,2§	pure trans N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-6-(4-thiomorpholiny)-4-pyrimidinamine	(304)		+48.7
125	1 HCl	B-1§,2§	pure trans N-cyclopropyl-5-methyl-2-(2-methylcyclopropyl)-6-(4-thiomorpholiny)-4-pyrimidinamine	(304)		-52.0
126	1 HCl	A-1§,2§	pure trans N-cyclopropyl-2-(2-methylecyclopropyl)-6-(4-thiomorpholiny)-4-pyrimidinamine	(290)		+66.9
127	1 HCl	B-1§,2§	pure trans N-cyclopropyl-2-(2-methylecyclopropyl)-6-(4-thiomorpholiny)-4-pyrimidinamine	(290)		-68.6
128	1 maleate	achiral	N ⁴ -benzyl-N ⁶ ,2-dicyclopropyl-5-methyl-4,6-pyrimidinediamine	295		
129	1 maleate	achiral	N ⁴ -benzyl-N ⁶ ,2-dicyclopropyl-N ⁴ ,5-dimethyl-4,6-pyrimidinediamine	309	74.5	
130	1 HBr	A-1,2	rac trans N ⁴ -benzyl-N ⁶ -cyclopropyl-2-(2-methylecyclopropyl)-4,6-pyrimidinediamine	(294)		
131	1 maleate	achiral	N ⁴ ,2-dicyclopropyl-5-methyl-N ⁶ -[2-(methylsulfanyl)benzyl]-4,6-pyrimidinediamine	341	132.7	
132	1 maleate	achiral	N ⁴ ,2-dicyclopropyl-N ⁶ -(2,6-difluorobenzyl)-5-methyl-4,6-pyrimidinediamine	331	162.7	

Salt/solvate		Configuration data	Free base IUPAC NAME	MH ⁺ [M ⁺]	DSC °C (mp)	alphaD	
133	1 maleate	achiral	N ⁴ ,2-dicyclopropyl-N ⁶ -(2-fluorobenzyl)-5-methyl-4,6-pyrimidinediamine	313	141.9		
134	1 HCl	A-1,2	rac	trans N ⁴ -cyclopropyl-N ⁶ -methyl-2-(2-methylcyclopropyl)-N ⁶ -(2-nitrobenzyl)-4,6-pyrimidinediamine	354		
135	1 maleate	achiral	N ⁴ -[3,5-bis(trifluoromethyl)benzyl]-N ⁶ ,2-dicyclopropyl-5-methyl-4,6-pyrimidinediamine	431	170.8		
136	1 maleate	achiral	N ⁴ ,2-dicyclopropyl-N ⁶ -(3,5-difluorobenzyl)-5-methyl-4,6-pyrimidinediamine	331	184.9		
137	1 maleate	achiral	N ⁴ -cycloheptyl-N ⁶ ,2-dicyclopropyl-5-methyl-4,6-pyrimidinediamine	301	136.1		
138	1 maleate	A-1,2	rac	trans N ⁴ -cycloheptyl-N ⁶ -cyclopropyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediamine	301		
139	1 maleate	achiral	N ⁴ -cyclohexyl-N ⁶ ,2-dicyclopropyl-N ⁴ ,5-dimethyl-4,6-pyrimidinediamine	301	(136-137)		
140	1 maleate	achiral	5-chloro-N ⁴ -cyclohexyl-N ⁶ ,2-dicyclopropyl-4,6-pyrimidinediamine	307/309	62.9		
141	1 maleate	achiral	N ⁴ -cyclohexyl-N ⁶ ,2-dicyclopropyl-5-methyl-4,6-pyrimidinediamine	287	159.7		
142	1 maleate	A-1,2	rac	trans N ⁴ -cyclohexyl-N ⁶ -cyclopropyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediamine	287	174.3	
143		A-1S,2S	pure	trans N ⁴ -cyclohexyl-N ⁶ -cyclopropyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediamine	287	65.25	

Salt/solvate	Configuration data	Free base IUPAC NAME	MH ⁺ (M ⁺)	DSC °C (mp)	alpha/D
144	B-1S,2S pure	trans N ⁴ -cyclohexyl-N ⁶ -cyclopropyl-2-(2-methylcyclopropyl)-4,6-pyrimidinediamine	287		-54.4
145 1 maleate	mixt	cis & trans N ^{4,2} -dicyclopropyl-5-methyl-N ⁶ -(4-methylcyclohexyl)-4,6-pyrimidinediamine	301	166.0	
146	A pure	cis or trans N ^{4,2} -dicyclopropyl-5-methyl-N ⁶ -(4-methylcyclohexyl)-4,6-pyrimidinediamine	301		
147	achiral	1-[2-cyclopropyl-6-(cyclopropylamino)-5-methylpyrimidin-4-yl]azepan-2-one	301		
148 1 maleate	achiral	N,2-dicyclopropyl-6-(3,4-dihydro-2(1H)-isoquinoliny)-5-methyl-4-pyrimidinamine	321	196.0	
149	achiral	N,2-dicyclopropyl-6-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-5-methyl-4-pyrimidinamine	331	111.0	
150 1 maleate	achiral	N ^{4,2} -dicyclopropyl-N ⁶ -(2,2-diphenylethyl)-5-methyl-4,6-pyrimidinediamine	385	157.4	
151 1 maleate	1,5 mixt	N,2-dicyclopropyl-5-methyl-6-(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)-4-pyrimidinamine	341		
152 1 maleate	A-4a,8a rac	trans N ^{2,2} -dicyclopropyl-5-methyl-6-octahydro-2(1H)-isoquinoliny-4-pyrimidinamine	327		
153 1 HCl	achiral	6-(8-azaspiro[4.5]dec-8-yl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	327		
154 1 maleate	achiral	6-(1-azepany)-2-cyclopentyl-N-cyclopropyl-5-methyl-4-pyrimidinamine	315		

Salt/solvate		Configuration data	Free base IUPAC NAME	$\text{MH}^+(\text{M}^+)$	DSC °C (mp)	alphaD
155		achiral	4-azepan-1-yl-2-cyclopropyl-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine	273		
156		achiral	4-azepan-1-yl-2-cyclopropyl-6,7,8,9-tetrahydro-pyrimido[4,5-blazepine	287		
157		achiral	4-azepan-1-yl-2-cyclopropyl-6,7-dihydro-pyrrolo[2,3-d]pyrimidine			
172	1 fumarate	IR,2R&1S,2S	rac trans 6-(1-azepanyl)-2-cyclopropyl-5-methyl-N-(2-methylcyclopropyl)-4-pyrimidinamine	301	138.0	
173	1 maleate	1,2	rac trans {1-[6-(cyclopropylamino)-2-(2-methylcyclopropyl)-4-pyrimidinyl]-4-piperidiny}-2-(2-methylcyclopropyl)-4-pyrimidinamine	303	127.6	
174	1,5 fumarate		6-(1-azepanyl)-2-cyclopropyl-5-methyl-N-(1-methylcyclopropyl)-4-pyrimidinamine	301		
175	1 maleate	achiral	N,2-dicyclopropyl-5-methyl-6-(1-piperidiny)-4-pyrimidinamine	273	110.1	
176	1 maleate	achiral	6-(3-azabicyclo[3.2.2]non-3-yl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine	313		
177	1 fumarate	2	rac N,2-dicyclopropyl-5-methyl-6-(2-methyl-1-piperidiny)-4-pyrimidinamine	287	186.3	
178		achiral	N ⁴ ,2-dicyclopropyl- N ⁶ -(4-fluorobenzyl)-5-methyl-4,6-dipyrimidinediamine	313		
179		achiral	N ⁴ ,2-dicyclopropyl-5-methyl-N ⁶ -(2-methylbenzyl)-4,6-dipyrimidinediamine	309		

Salt/solvate		Configuration data	Free base IUPAC NAME	MH ⁺ (M ⁺)	DSC °C (mp)	alpha D
180		achiral	N,2-dicyclopropyl-5-methyl-6-(1-pyrtolidinyl)-4-pyrimidinamine	259		
181	1 fumarate	1R,2S & 1S,2R	rac	trans 6-(1-azepanyl)-2-cyclopropyl-5-methyl-N-(2-phenylcyclopropyl)-4-pyrimidinamine	363	156.2
182			achiral	1-[6-(3-bromoazetidin-1-yl)-2-cyclopropyl-5-methylpyrimidin-4-yl]azepane	365/367	88.0
183			achiral	1-[6-azepan-1-yl-2-cyclopropyl-5-methylpyrimidin-4-yl]azetidine-3-carbonitrile	312	
184	1 maleate		achiral	1-(6-azetidin-1-yl-2-cyclopropyl-5-methylpyrimidin-4-yl)azepane	287	102.6
185			achiral	1-[2-cyclopropyl-5-methyl-6-(3-methylazetidin-1-yl)pyrimidin-4-yl]azepane	301	
186	1.5 fumarate		achiral	1-[2-cyclopropyl-5-methyl-6-(3-methylazetidin-1-yl)pyrimidin-4-yl]azepane	301	96.5
187	2 fumarate		achiral	1-[2-cyclopropyl-5-methyl-6-(3-methylazetidin-1-yl)pyrimidin-4-yl]azepane	301	102.2
188			achiral	1-[2-cyclopropyl-6-(3,3-dimethylazetidin-1-yl)-5-methylpyrimidin-4-yl]azepane	315	
189	1 maleate		achiral	1-(6-azepan-1-yl-2-cyclopropyl-5-methylpyrimidin-4-yl)azetidin-3-ol	303	137.7
190			achiral	1-[6-azepan-1-yl-2-cyclopropyl-5-methylpyrimidin-4-yl]azetidin-3-yl methanesulfonate	381	100.4

Salt/solvate		Configuration data	Free base IUPAC NAME	MH ⁺ (M ⁺)	DSC °C (mp)	alpha/D
191	1 fumarate	achiral	1-[2-cyclopropyl-6-(3-methylazetidin-1-yl)pyrimidin-4-yl]azepane	287	159.1	
192		achiral	1-(6-azetidin-1-yl-2-cyclopropylpyrimidin-4-yl)azepane	273	77.5	
193	1 H ₂ O	achiral	1-[6-azepan-1-yl-2-cyclopropyl-5-methylpyrimidin-4-yl]azetidin-3-one	319		
194		achiral	1-[2-cyclopropyl-6-(3-fluoroazetidin-1-yl)-5-methylpyrimidin-4-yl]azepane	305		
195	1.5 fumarate	achiral	1-[2-cyclopropyl-6-(3-fluoroazetidin-1-yl)pyrimidin-4-yl]azepane	291	129.9	
196	1 maleate	achiral	1-[2-cyclopropyl-6-(3-methoxyazetidin-1-yl)-5-methylpyrimidin-4-yl]azepane	317		

Compound **97** was resolved into its enantiomers by chromatography on a chiral support (Chiraldpak AD Daicel, isopropanol/isohexane/diethylamine 5/95/0.1 (v/v), 30 °C) to give compound **99** (first eluted) and compound **100** (second eluted).

Compound **65** was resolved into its enantiomers by chromatography on a chiral support (Chiraldpak AD Daicel, isopropanol/isohexane/diethylamine 5/95/0.1, 30 °C) to give compound **67** (second eluted) and compound **68** (first eluted).

Compound **142** was resolved into its enantiomers by chromatography on a chiral support (Chiraldpak AD Daicel, isopropanol/isohexane/diethylamine 3/97/0.1, 30 °C) to give compound **143** (first eluted) and compound **144** (second eluted).

Compound **101** was resolved into its enantiomers by chromatography on a chiral support (Chiraldpak AD Daicel, isopropanol/hexane mixture 4/96, 30 °C) to give compound **104** (first eluted) and compound **105** (second eluted).

EXAMPLE 8: affinity for human muscarinic receptors.

Chinese Hamster Ovarian cells (CHO) expressing the human recombinant m1, m2, m3, m4 and m5 receptors were cultured in Ham's F12 media supplemented with 100 IU/ml of penicillin, 100 µg/ml of streptomycin, 400 µg /ml of geneticin and 5 % of fetal bovine serum. Cell cultures were maintained in a humidified incubator at 37 °C and 5 % CO₂.

Confluent CHO cells expressing human m1, m2, m3, m4 and m5 muscarinic receptors were harvested and resuspended in phosphate buffered saline without calcium and magnesium. The cell suspension was centrifuged at 1500 x g for 3 min (4 °C). The cell pellet was homogenized in a 15 mM Tris-HCl (pH 7.5) buffer containing 2 mM MgCl₂, 0.3 mM EDTA and 1 mM EGTA. The crude membrane fraction was collected by two consecutive centrifugation steps at 40,000 x g for 25 min (4 °C). The final pellet was resuspended, at a protein concentration ranging from 2 to 6 mg/ml, in a 7.5 mM Tris-HCl (pH 7.5) buffer containing 12.5 mM MgCl₂, 0.3 mM EDTA, 1 mM EGTA and 250 mM sucrose and stored in liquid nitrogen.

Binding assays were performed according to procedure described in: Buckley N.J., Bonner T.I., Buckley C.M., Brann M.R., Mol. Pharmacol. (1989), 35, 469-476, but with slight modifications.

Briefly, 25 to 50 µg of membrane proteins were incubated at room temperature in 1 ml of a 50 mM Tris-HCl (pH 7.4) buffer containing 2 mM of MgCl₂, 0.1 nM of [³H]-NMS (N-methylscopolamine, 85 Ci/mmol, from Apbiotech, UK) and increasing concentrations of test compound dissolved in DMSO (1 % final concentration). Non specific binding was measured in the presence of 1 µM atropine. After 60 (m2) or 120 (m3) min. incubation, assays were stopped by rapid vacuum filtration of the samples through glass fiber filters (Filtermat A, Wallac, Belgium) presoaked in 0.3 % polyethyleneimine for at least 2 h. Samples were further rinsed with 8 ml of ice-cold 50 mM Tris-HCl (pH 7.4) buffer. Radioactivity trapped onto the filter was counted in a Betaplate counter (Wallac). Competition binding curves were analyzed by non-linear regression with XLfit software (IDBS, UK).

30

EXAMPLE 9: PDE IV enzymatic activity.*Enzyme source:*

Cytosolic fraction from U937 cells pre-stimulated for 4 h at 37 °C with a mixture of rolipram 30 µM and salbutamol 1 µM (Torphy T.J., Zhou H.L., Cieslinski L.B., J. Pharmacol. Exp. Ther. (1992), 263 (3), 1195-1205).

SPA Phosphodiesterase assay (Amersham Pharmacia Biotech; Belgium):

Assays were performed in 100 μ L of 50 mM Tris HCl buffer (pH 7.4) containing 5 mM MgCl₂, 2 mM EGTA, 20 nM of [³H]-cAMP (40-60 Ci/mmol), the cytosolic fraction of 50,000 U937 cells and the appropriate concentration of test compound (usually 10 μ M) dissolved in DMSO (final assay concentration not exceeding 1 %). After 30 min incubation at room temperature, 0.5 mg of SPA yttrium silicate beads are added to each sample. Radioactivity bound to the beads (5'-AMP) is determined by liquid scintillation. Non PDE IV activity and/or non specific binding of the labeled substrate to the SPA beads is defined as the residual radioactivity remaining in the presence of rolipram 32 μ M (non PDE IV activity represents about 40 % of total activity). PDE IV activity is determined by subtracting the non PDE IV activity from the total activity.

Compounds according to the invention showed pIC₅₀ values ranging from 6.5 to 10 for the m3 receptor, and showed pIC₅₀ values ranging from 5.7 to 8 for PDE IV. Dual high affinities were especially shown by compounds 55, 56, 57, 59, 60, 61, 62, 63, 64, 65, 66, 67, 72, 77, 78, 79, 80, 86, 87, 94, 95, 98, 106, 112, 115, 118, 119, 132, 144, 145, 154, 155, 156, 175, 176, 177, 180, 184, 185, 186, 187, 189, 191, 192 and 194.

EXAMPLE 10: *in vitro* inhibition of carbachol-induced contraction of guinea-pig trachea.

The method was developed according to the procedure described in Leff P., Dougall I.G., Harper D., Br. J. Pharmacol. (1993), 110, 239-244. Tracheal rings were prepared from male Dunkin-Hartley guinea pig. Tissues were mounted in 20 ml organ baths containing modified Krebs' solution in the presence of 3.10⁻⁶ M indomethacin, 3.10⁻⁴ M hexamethonium and 10⁻⁶ M propranolol. The bathing solution was maintained at 37 °C and gassed with 95 % O₂-5 % CO₂. Tissues were allowed to equilibrate for a period of 60 min under a resting tension of 1 g. Isometric contractions were measured by force-displacement transducers coupled to an IOX computer system capable of controlling automatic data acquisition and bath washout by automatic fluid circulation through electrovalves at defined times. Drugs were manually or robotically injected into the bath according to the stability of the measured signal.

At the end of the 60 min period of stabilisation, the tracheas were contracted twice with 10⁻⁶ M carbachol at 30 min intervals. Two cumulative concentration-response curves were successively constructed in the absence or presence of the test

compound (incubation time: 1 hour). Results were obtained from at least 3 or 4 individual experiments. Control tissues were treated with the solvent.

Antagonistic potency of the test compound was estimated by the calculation of pD₂' and /or pA₂ values according to the methods described by Van Rossum (Van Rossum J.M., Hurkmans J.A.T.M., Wolters C.J.J., Arch. Int. Pharmacodyn. Ther. 5 (1963), 143, 299-330) or Arunlakshana & Schild (Arunlakshana O., Schild H.O., Br. J. Pharmacol. (1959), 14, 48-58).

Preferred compounds according to the invention show pA₂ values typically ranging from 5.5 to 8.